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L-pipecolic acid (L-PA), a six carbon imino acid, is an intermediate of lysine
degradation in various organisms including bacteria, yeast, fungi and mammals. In
primates, the oxidation of L-PA by the enzyme L-pipecolate oxidase (L-PO) is the rate
determining step of L-lysine degradation in the central nervous system. This thesis
describes efforts to probe the L-PO mechanism by using different heteroatom substrate
analogs as 'alternative substrates and inactivators of the enzyme.
Thirteen heterocyclic analogs of L-PA containing nitrogen, oxygen and sulfur have
been synthesized and tested as inhibitors and alternate substrates of L-PO. The oxygen
analog, (R, S)-1,3-oxazine-4-carboxylic acid is neither an inhibitor nor a substrate of the
enzyme, while nitrogen analogs such as (S)-3,4,5,6-tetrahydropyrimidine-4-carboxylic
acid and (S)-hexahydropyrimidine-4-carboxylic acid proved to be weak substrates and
inhibitors. Sulfur analogs have proved to be the best inhibitors and alternate substrates of
L-PO. These include the mechanism-based inactivator and excellent substrate (S)-1,3-
thiazane-4-carboxylic acid. (S)-1,4-Thiazane-4-carboxylic acid is also an excellent substrate
with a higher binding affinity for L-PO than the natural substrate.
The turnover product of (S)-1,3-thiazane-4-carboxylic has been characterized by
derivatization, HPLC analysis and mass spectrometry to be homocysteine. The turnover
product of (S)-1,4-thiazane-2-carboxylic acid was also characterized and shown to be L-a-
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OF L-PIPECOLATE OXIDASE
 
CHAPTER 1
 
BACKGROUND AND INTRODUCTION
 
L-PIPECOLATE OXIDATION AND LYSINE DEGRADATION 
L-Pipecolic acid (Figure 1.1) is a nonprotein amino acid and is the higher homolog 
of L-proline. It has a widespread occurrence in Nature and is a minor product of L-lysine 
degradation in bacteria,' fungi,2 yeasts,3 plants4 and mammals.5 Pipecolic acid oxidation 
was subjected to extensive studies as early as the 1960s. By studying the metabolism of L­
pipecolic acid (L-PA) in certain Pseudomonas species which can survive on L-PA as a sole 
source of carbon and nitrogen, Rodwell and co-workers showed that L-PA goes through a 
flavin-dependent dehydrogenation to A1-piperideine-6-carboxylic acid (A1-P6C), which 
spontaneously hydrates to  form L-a-aminoadipate-8-semialdehyde.6  Later  it  was 
demonstrated that L-PA oxidation is also a central step of lysine metabolism in animals 
such as rats,7 guinea pigs,8 turkeys 9 and human beings.10 
5 
Fig.1.1 Structure of L-Pipecolic Acid (L-PA) 2 
Degradation of lysine in the mammalian system takes many diversified routes,'° 
although the major pathway is believed to be via L-saccharopine (EN-(L-glutar-2-y1)-L­
lysine).11 The L-saccharopine pathway (Scheme 1.1) involves the sequential action of L-
lysine ketoglutarate reductase and sacchropine dehydrogenase to form L-a-aminoadipate­
8-semialdehyde. Although this is the major pathway in liver and other tissues, it is not 
believed to be very active in the brain based on the negligible activities of lysine 
ketoglutarate reductase and saccharopine dehydrogenase in this tissue.5,12 In the central 
nervous system (CNS), L-lysine is mainly metabolized via the L-pipecolate pathway 
(Scheme 1.1).13 In this pathway, the initial step involves oxidative deamination of lysine 
to form a- keto -E- aminocaproic acid. The following step is spontaneous cyclization to Al­
piperideine-2-carboxylate (A' -P2C), which is stereospecifically reduced to L-pipecolic 
acid. The subsequent step involves the oxidation of L-PA to  A' -P6C,  which 
spontaneously hydrates to give L-a-aminoadipate-8-semialdehyde, the first common 
intermediate for both pathways. The semialdehyde is further oxidized to L-a-anainoadipic 
acid by L-a-aminoadipate oxidoreductase.14 The pipecolate pathway is also found in 
animal liver, but the precursor to pipecolate is D-lysine instead of the L-isomer.15 
The type of enzyme catalyzing the oxidation of L-PA has been found to be species 
dependent. In primates, including humans, L-PA is oxidized by a flavin-dependent 
peroxisomal  oxidase which requires  molecular oxygen and  generates  hydrogen 
peroxide.16 In lower mammals, a mitochondrial dehydrogenase coupled to the electron 
transfer chain is responsible for the L-PA oxidizing activity.17 In both systems, L­
pipecolic acid oxidation is suggested to be the rate-limiting step in the formation of L-a­
aminoadipic acid.12 3 
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Scheme 1.1 Saccharopine and Pipecolate Pathways of Lysine Degradation 
PROPER11E,S AND ASSAYS OF L- PIPECOLATE OXIDASE 
L-Pipecolate oxidase (L-PO: EC 1.5.37) is a membrane-associated peroxisomal 
enzyme requiring molecular oxygen and generating hydrogen peroxide and was first 
isolated from monkey liver by Mihalik's group.18 The enzyme, a yellow monomer, has a 
molecular weight of 46 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and a high pI of 8.9, characteristic of peroxisomal enzymes. 
The enzyme contains a covalently bound flavin cofactor with absorption maxima at 457 
and 383 nm. L-PO exhibits a KM of 3.7 mM and a Vmax of 2.1 mmolimin-inn --1 for L- g 4 
pipecolic acid as substrate. In the same study, benzoic acid was found to be a competitive 
inhibitor of L-PO with a Ki of 0.75 mM. By using HPLC to compare the derivatized 
reaction product to an authentic sample, Rao and Chang have identified L-a-aminoadipate­
5-semialdehyde as the isolable product of this enzyme reaction.19 
Because of the production of hydrogen peroxide, L-PO activity can be measured 
by a horseradish peroxidase-linked assay, which couples hydrogen peroxide production 
from the oxidase reaction to the oxidation of the dye o-dianisidine catalyzed by horseradish 
peroxidase.'8 The oxidation is monitored by measuring the absorption change at 460 nm 
on a UV/vis spectrophotometer. A more sensitive direct assay method was developed by 
Rao and Chang, which requires a minimum of 16 pg of protein compared to the 100 1.4 
needed for the spectrophotometric assay.2° In the radioassay, the L-a-amino-[2,3,4,5,6­
3H]-adipate-8-semialdehyde, formed as a direct reaction product of L42,3,4,5,6-314)­
pipecolic acid oxidation, is trapped by sodium bisulfite (Scheme 1.2). The adduct can be 
separated from the substrate by cation exchange chromatography. After interaction with 
sodium bisulfite, the turnover product has a net negative charge and does not bind to the 
cation exchange resin. 
HSO; + H20 
OS0-2 H + + CHO 
H  02C° I-120  02C'  NH3  NH3  OH 
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Scheme 1.2  Bisulfite Adduct Formation in L-PO Radio Assay 5 
PHARMACOLOGICAL AND PHYSIOLOGICAL
 
ROLE OF L-PIPECOLIC ACID
 
Because of the possible physiological role of L-PA in the central nervous system 
(CNS), its role in this tissue has been subjected to intensive study in mammalian systems. 
L-PA is one of the three cyclic secondary amino acids present in the brain, along with 
proline and 4-hydroxyproline.21 It was reported that the regional distribution of L-PA in 
the dog brain ranged between values of 1 to 10 nmol/g.22 A similar range of concentration 
of L-PA has also been reported in the brain of mice17 and rats.23 In normal humans, L-PA 
concentration in plasma is 12 ± 5.6 j.IM at birth and decreases during the first several 
months of life to 2.1 ± 1.6 jiM where it remains through adulthood.24 
During recent years, evidence has accumulated suggesting a possible relationship 
between L-PA and 7-aminobutyric acid (GABA) receptors in cortical and hippocampal 
neurons in the central nervous system.25 Neurophysiological studies in the rat suggested 
that L-PA is a putative neurotransmitter which might modulate GABAergic transmission in 
the CNS .26 This influence was attributed to the inhibition of neuronal GABA uptake 
and/or enhancment of its release through the pre-synaptic GABAA receptor.25 
Because the central GABAA receptor is the site of action for many CNS-active 
drugs, the anticonvulsant activity of L-PA was investigated.  It was reported that 
intraperitoneal injection of L-PA significantly increased clonic and tonic latencies in a dose-
dependent manner against 90 mg/kg pentylenetetrazole (PTZ) induced seizures.27 
Furthermore, L-PA potentiates the suppressing effects of hexobarbitol on electrically- and 
chemically-induced convulsions, suggesting it could be a useful anticonvulsant agent 
through modifying central GABA-mediated conduction.28,29 It has been reported that 
administration of L-PA protected mice against  bicuculline- and picrotoxin-induced 
convulsions.30 In this study, it was found that intrathecal injections of L-PA produced a 6 
dose-related increase in the latency of the onset of these convulsions as well as a decrease 
in their duration.30 
The physiological significance of L-PA and the pipecolate pathway of  lysine 
degradation was not fully appreciated until the observation of L-PA accumulation in the 
brain, serum and urine of patients with peroxisomal disorders, such as Zellweger 
syndrome,31 hyperlysinemia,32 and hyperpipecolatemia.33 These patients typically have 
severe neurological dysfunction and profound mental retardation which are associated with 
the loss of most peroxisomal metabolic functions.33 The L-PA concentration  has been 
found to be as high as 200 iimolig in the patient's brain tissues and 31.9 ± 10.7 AM in the 
plasma, compared to the normal value of 2.1 p.M.34 
An oral loading test with L-pipecolic acid indicated that the accumulation  of 
pipecolic acid was due to an impairment in pipecolic acid degradation.35 Further research 
found that L-PO was deficient in the liver of Zellweger patients.31  It was speculated that 
in hyperlysinemia patients, the normal L-saccharapine pathway for L-lysine  degradation is 
blocked and the increased levels of L-PA are due to an overload of this  secondary 
pathway.32 
L-PA is also found excreted in the urine of premature and very young infants, but 
not in older normal infants and normal adults.32 The formation of L-PA from L-lysine 
could be detected in mouse brain as early as the 17th day of gestation.36 A slight increase 
in formation occurs up to the first day after birth; however, at 90 days, the concentration is 
back to perinatal values.36  Also, the uptake of L-PA in the one-day-old mouse brain 
shows a different pattern than that in the adult.36 These data suggest that L-PA may play a 
role in the development of CNS. 
Because knowledge of L-PA metabolism is important to understand these lysine 
degradation disorders and because L-PO may play an important role in the development of 
potential therapeutic agents, the area has been subject to extensive  studies.18,37,38 The 
focus of this thesis project is on designing and synthesizing alternative substrates and 7 
inhibitors of L-PO, specifically mechanism-based inactivators, to probe the enzyme 
mechanism. 
ALTERNATE SUBSTRATES & INHIBITORS
 
IN ENZYMOLOGY STUDIES
 
In recent years, enzyme alternate substrates and inhibitors not only have made 
significant contributions to the understanding of enzymatic mechanisms, but also have 
provided an increasing number of patented therapeutic agents for the treatment of diseases. 
These substrates and inhibitors act on the target enzymes by influencing the binding of a 
natural substrate and its turnover. In basic research, enzyme alternate substrates and 
inhibitors are commonly used to probe the chemical and conformational nature of a 
substrate-binding site as part of an effort to elucidate the enzyme's catalytic mechanism. 
For example, a covalent binding mechanism-based inactivator may be used to identify 
active site amino acid residues which could potentially be involved in the catalytic 
mechanism of the enzyme.39 Reversible, competitive inhibitors may be used to facilitate 
enzyme purification by using the inhibitor as a ligand for affinity chromatography 4o In 
medicine, these inhibitors have potential as drugs by selectively blocking certain metabolic 
pathways, decreasing the concentration of enzymatic product or altering the concentration 
of an enzyme's substrate. In fact, about half of the top 20 drugs sold worldwide are 
enzyme inhibitors .41 
All the inhibitors studied in this project fall into either the competitive inhibitor or 
mechanism-based inactivator category. A competitive inhibitor is a substrate that directly 
competes with the natural substrate for an enzymatic-binding site. Usually, such an 
inhibitor structurally resembles the natural substrate to the extent that it specifically binds 
to the active site but differs from it so as to be unreactive. Competitive inhibitors usually 
follow the reaction model in Scheme 1.3. Because the enzyme-inhibitor complex is 8 
catalytically inactive, a competitive inhibitor acts by reducing the concentration of free 
enzyme available for natural substrate binding and turnover. 
E + S  E S  E + P 
E: Enzyme 
S: Substrate 
I:  Inhibitor 
P: Product 
EI 
Scheme 1.3 General Reaction Model of Competitive Inhibition 
Mechanism-based inactivators are typically unreactive compounds which are only 
converted into highly reactive species when subjected to the normal catalytic mechanism of 
the target enzyme. Mechanism-based inactivation usually follows the model in Scheme 
1.4. 
E + I  EI  E I'  E-I" 
E: Enzyme 
i  I:  Inhibitor 
E + I' 
Scheme 1.4: General Reaction Model of Mechanism-Based Inactivator 
As a relatively newly discovered type of enzyme inhibitor, mechanism-based 
inactivators were not subjected to intensive study until the 1970s. They have proven to be 
very useful in the study of enzyme mechanisms and in the design of highly specific,  low-
toxicity drugs.41 Criteria have been developed for the evaluation of a possible mechanism-
based inactivator.41 More often than not, only a few of these criteria are tested when a 
potential mechanism-based inactivator is studied. However, to truly characterize an 9 
inactivator as falling into this class, most or all of the criteria should be satisfied. These 
criteria are: 
1. A time-dependent loss of enzyme activity (usually, but not necessarily, pseudo-first 
order with respect to enzyme) is observed. 
2. The rate of inactivation is proportional to the concentration of inhibitor at low inhibitor 
concentration, but independent at high concentration (saturation kinetics). 
3. The rate of inactivation is slower in the presence of a natural substrate or competitive 
inhibitor than in its absence. That is, the inactivation is protected by a natural substrate 
and indicates the inactivator is acting at the enzyme active site. 
4. Enzyme activity does not return upon dialysis or gel filtration. This means that the 
inactivation is irreversible. 
5. A 1:1 stoichiometry of radioactively labeled inactivator to active site usually results after 
inactivation followed by dialysis or gel filtration. 
6. A catalytic step for conversion of the inactivator to a reactive intermediate can be 
demonstrated. 
7. Inactivation should occur prior to the release of any activated species. The presence of 
exogenous nucleophiles or radical traps has no effect on the inactivation rate, and 
following inactivation, a second equal addition of enzyme results in the same rate of 
inactivation as the first addition. 
For this study, mechanism-based inactivators can be used to probe the L-P0 
mechanism by providing clues to possible reactive intermediates. Also, they represent 
potential therapeutic agents for treating convulsive disorders. Competitive inhibitors are 
useful tools to study the electronic properties and steric limitations in the active site of L­
PO. With alternate substrates, we can study the mechanism by observing the effect that 
substrates with altered electronic properties and oxidation potentials have on the rate of the 
reaction. 10 
These inhibitors may also fmd use as potential agents to decrease the level of L-a­
aminoadipic acid in the central nervous system. L-oc-Aminoadipic acid, a product of lysine 
metabolism, exists in mammalian brain in micromolar concentration. Its properties as a 
postsynaptic excitatory amino acid receptor agonist,42 excitotoxin,43 and gliotoxin44 are 
well documented. It was also reported that the accumulation of L-a-aminoadipic acid could 
lower the level of kynurenic acid in the CNS.38 Kynurenic acid is a tryptophan metabolite 
which serves as one of the brain's defenses against overactivation of excitatory amino acid 
receptors and pathological consequences, such as excitotoxicity and seizures.38  Thus, 
when the level of L-a-aminoadipic acid is decreased by these L-PO inhibitors, kynurenic 
acid levels should remain unaffected. 
MECHANISM MODELS FOR L-PIPECOLIC OXIDASE 
The design of mechanism-based inactivators and alternative substrates requires at 
least some understanding of the enzyme binding site in order to promote the formation of 
the initial noncovalent enzyme substrate or inhibitor complex. Also, some knowledge of 
the mechanism of the target enzyme with its normal substrate is important in the design. 
The amino acid sequence of L-PO has not been published, the active site has not been 
characterized, and little is known about the L -PO mechanism. To design the target 
compounds in this study, another well-studied flavoenzyme was used as a model for the 
possible mechanism of L-PO. 
L -PO is a flavin-dependent amine oxidase, belonging to the same family of 
enzymes as the well-studied monoamine oxidase (EC 1.4.3.4). It is generally accepted that 
the oxidation reaction catalyzed by monoamine oxidase (MAO) proceeds by a single-
electron mechanism (Scheme 1.5).45 In this mechanism, it is proposed that the first step 
involves a one-electron transfer from the substrate amino group to the oxidized flavin (Fl) 11 
to give the amine radical cation (3) and the flavin semiquinone (F1!). Loss of a proton 
(pathway a) gives the a-amino radical (4) which can either transfer a second electron to 
the flavin semiquinone to give reduced flavin (Fla-) (pathway b) or undergo a radical 
combination with an active site radical (pathway c) to give a covalent adduct, which should 
decompose by 13-elimination to give the iminium ion. A potential alternative to proton 
transfer (pathway a) is hydrogen atom transfer (pathway d), which bypasses the a-amino 
radical intermediate (4). 
Fly  F1H 
d 
1 Fl  Fil	 
14+  Fll  F1H  / 
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Scheme 1.5: Single-Electron Transfer Mechanism Proposed for Monoamine Oxidase 
In order to detect the formation of radical intermediates, a chemical approach has 
been used by Silverman. One approach has been  to  synthesize  a  variety  of 
cyclopropylamine substrate analogs, which are mechanism-based inactivators of MAO.46 12 
The selection of this group was based on the known chemistry47 that secondary aminyl 
radicals could be observed. But when the corresponding cyclopropylaminyl radical was 
generated by the same method, it could not be observed; instead, the ring-cleaved carbinyl 
radical was detected. Upon incubation of these compounds with MAO, the enzyme was 
irreversibly inactivated (Scheme 1.6). The formation of aminyl radical followed by 
cyclopropyl ring cleavage and attachment to  the enzyme were deduced through 
identification of the stable intermediates. The results were consistent with a one-electron 
oxidation of the cyclopropyl substrate analogs to the amine radical cation followed by 
homolytic ring cleavage and attachment to the enzyme. 
Flox  Fl 
IT 
H30+ 
0
 
Scheme 1.6 Proposed Mechanism of Inactivation of MAO by Cyclopropyl Substrates 
Silverman and coworkers have also studied the inhibition of MAO by  1­
phenylcycl obutylamine.48 The cyclobutylamine would undergo a known one-electron 
rearrangement which triggers cyclobutyl ring cleavage  after generating the  initial 
cyclobutyl amino  radical (Scheme 1.7).49 The observed formation of 2-phenyl-I 
pyrroline supports the initial formation of the 1-phenyl-cyclobutylaminyl radical. When 13 
(aminomethyl)cubane was reacted with MAO, the identified turnover products also 
strongly support the single electron transfer mechanism through electron transfer followed 
by proton transfer.50 
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Scheme 1.7 Proposed Mechanism of Inactivation of MAO by 1-Phenylcyclobutylamine 
Another reasonable mechanism for MAO is the direct hydrogen atom abstraction 
mechanism proposed by Edmondson (Scheme 1.8).51 From stopped flow kinetic and 
kinetic isotope effect studies of substituted benzylamines, it was concluded that the rate-
determining step in the reaction was the C-H bond cleavage. These researchers proposed a 
direct hydrogen abstraction from the a-carbon of the substrate, followed by rapid electron 
transfer from the aminyl substrate radical to form the flavin semiquinone and the 
protonated imine product. Although this proposed mechanism is not supported by 
experimental results, such as spectroscopic evidence for a protein-bound radical, one of 
the considerations against the single-electron transfer mechanism is the unfavorably large 
difference in the redox potentials of the amine (approximately +1 V) and the flavin (-0.2 
V).52 The large difference in potentials would seem to make the transfer of electrons on 
the enzyme from the amine to a flavin energetically unfavorable  . 14 
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Scheme 1.8: Direct Hydrogen Abstraction Mechanism Proposed for Monoamine Oxidase 
Most important for our studies in both proposed mechanisms, radical intermediates 
are suggested to be, involved. Thus, inhibitors and alternative substrates which can 
stabilize radical species by various mechanisms may prove to be useful tools for studying 
L-P O. 15 
CHAPTER 2 
SYNTHESIS OF ALTERNATE SUBS'T'RATES AND INHIBITORS
 
OF L-PIPECOLATE OXIDASE
 
TARGET COMPOUND DESIGN 
Synthesizing and testing substrate analogs is one of the most effective ways to 
discover alternative substrates and inhibitors of an enzyme, especially when little 
information about the enzyme mechanism and active site is known.41 Because of the 
similarity in structure, these compounds can often fit into the enzyme substrate binding 
pocket. However, the minor modifications in structure may result in a significant change 
in noncovalent binding forces, such as electronic, van der Waal's, and hydrophobic 
interactions. The contribution of these modifications to the overall binding affinity of the 
analogs may result in blocking of the active site to prevent any further substrate binding 
and catalysis as well as provide information on the environment of the binding site. Since 
the active site and amino acid sequence of L-PO have not been characterized, the inhibitor 
design strategy draws on possible mechanisms of L-PO according to the well-studied 
model enzyme, monoamine oxidase (MAO). As mentioned in Chapter 1, L-PO and 
monoamine oxidase are both flavin-dependent amine oxidases. It is very possible that both 
share a great deal of similarity in the overall chemical mechanism. The possible 
mechanisms for L-pipecolate oxidase, illustrated in Scheme 2.1, are drawn from the 
proposed mechanisms for monoamine oxidase.45,53 16 
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Scheme 2.1 Possible Mechanisms of L-Pipecolate Oxidase 
One possible mechanism of L-pipecolate oxidase is a "single-electron transfer" 
mechanism, analogous to that proposed by Silverman for monoamine oxidase.45 The 
initial step proceeds through a one-electron transfer from the amine of a substrate to the 
flavin, resulting in the nitrogen radical cation and the flavin semiquinone. The second step 
involves either proton transfer (pathway a) to form an a-amino radical or hydrogen 
abstraction to form the iminium intermediate  Al-piperideine-6-carboxylate (A1-P6C) 
(pathway b). From the a-amino radical, two routes to Al-P6C  are possible. The first 
(pathway c) involves a radical pair combination with the semiquinone form of the flavin, 
followed by heterolytic cleavage to the fully reduced flavin and  A1-P6C. The other 
possible route (pathway d) involves a second single electron transfer from the substrate to 
the cofactor. 17 
Another possibility involves "direct hydrogen abstraction" analogous to the 
mechanism proposed by Edmondson for monoamine oxidase (pathway e).51 This route 
proceeds with a direct hydrogen abstraction from L-PA by an enzyme-bound radical 
species to form an a-amino radical. Electron transfer to the flavin is next involved to form 
Al-P6C. 
Because radical intermediates are proposed in both mechanisms, the ability to 
stabilize a radical intermediate may be one important element in the design of potent 
inactivators and mechanistic probes. Compounds able to stabilize a radical intermediate or 
which have lower oxidization potentials should serve as good alternate substrates and 
possible inactivators. 
It is well established that heteroatoms, such as oxygen, nitrogen and sulfur have an 
important role in the stabilization of adjacent carbon-centered radicals.54 This stabilization 
is due to the electron donation from the lone-pair electrons of the heteroatom. Moreover, 
theoretical calculations suggest that sulfur can use an antibonding n-type orbital to 
accommodate the additional electron to form an a-thioradical with less deviation from 
planarity, and thus greater stability, than an a-oxyradical.55 This enhancement can also be 
explained by the resonance structure shown in Figure 2.1 because sulfur can form one 
more possible resonance structure than oxygen and nitrogen.54 
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Figure 2.1 Resonance Structures of Carbon-Centered Radicals 
with Different Heteroatoms 18 
Figure 2.2 illustrates the substrate analogs synthesized as part of this thesis 
project. Different heteroatoms are introduced either at position 4 or 5 of the piperidine 
ring. These compounds may be divided into three groups. The first group of compounds 
has  the  3,4,5,6-tetrahydropyrimidine  ring  structure  and  includes  (S)- 3,4,5,6­
tetrahydropyrimidine-4- carboxylic  acid  (1)  and  (S)-2- amino 3,4,5,6­
tetrahydropyrimidine-4- carboxylic acid  (2).  These compounds were not viewed as 
mechanism-based inactivators or substrates, but rather were hoped to act as reversible 
inhibitors because the 1,4,5,6-tetrahydropyrimidine, one of the tautomers of the 
tetrahydropyrimidine structure, is a structural mimic of Al-P6C.56 
The second group has a saturated heterocyclic ring structure with nitrogen, oxygen 
or sulfur in position 5. Compounds in this group include (S)-hexahydropyrimidine-4­
carboxylic acid (3),  (R,  S)-1,3-oxazane-4-carboxylic acid  (4),  (S)-1,3-thiazane-4­
carboxylic acid (5), (R)-1,3-thiazane-4-carboxylic acid (6) and (2S, 4R)-, (2S, 4S)- and 
(2R, 4S)-2-methyl-1,3-thiazane-4-carboxylic acid (7, 8 and 9, respectively). Because the 
introduced heteroatoms are at the position a to the proposed radical center, we envisioned 
that these heteroatoms can stabilize the putative radical intermediate. 
The third group of compounds are piperidine derivatives with nitrogen or sulfur at 
position 4. These compounds include (S)-1,4-thiazane-3-carboxylic acid (10), (S)-1,4­
thiazane-3-carboxylic acid 1-oxide (11), (S)-1,4-thiazane-3-carboxylic acid 1-dioxide 
(12) and (R, S)-1,4-piperazine-2-carboxylic acid (13). These were selected as interesting 
compounds to study the effect of polar atoms or groups at position 4 on the conformation 
of the piperidine ring and on the ability to stabilize a radical 13 to that atom s4 19 
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Figure 2.2 Substrate Analogs of L-Pipecolic Acid 20 
Preparation of Tetrahydropyrimidines (1) and (2) 
It is known that the condensation of 1,3-diamino compounds with a nitrile group 
or its equivalent is one of the effective ways to prepare tetrahydropyrimidine derivatives 
(Scheme 2.2).56 The required optically active 2,4-diaminobutyric acid (14) is available in 
one step from L-(+)-glutamic acid via a Curtius rearrangement.57,58 The synthesis of (S)­
3,4,5,6- tetrahydropyrimidine -4- carboxylic acid (1) involves reaction of 14 with a 
formamidine salt.59 To synthesize (S)-2-amino-3,4,5,6-tetrahydropyrimidine-4-carboxylic 
acid (2), reaction of 14 with cyanogen bromide under basic conditions was adopted.6° 
Under these conditions, the amine group is uncharged and capable of nucleophilic attack at 
the electrophilic carbon atom of the nitrile group. 
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Scheme 2.2. Preparation of Compound 1, 2 and 3 21 
Preparation of Pipecolate Analogs with Heteroatoms at Position 5 
(S)-Hexahydropyrimidine-4-carboxylic acid (3) was prepared by the condensation 
of (S)-1,3-diaminobutyric acid (14) with formaldehyde (Scheme 2.2).59 This reaction 
involves the formation of a Schiff s base intermediate and then nucleophilic attack at the 
imine carbon by the second amino group completes the cyclic structure. 
In a manner similar to the preparation of 3, (R, S)-1,3-oxazine-4-carboxylic acid 
(4) was synthesized through the condensation of D,L- homoserine and formaldehyde 
(Scheme 2.3). The cyclic product is formed through the reversible formation of an imine 
(Schiffs base) between the amino group and aldehyde, which is subject to nucleophilic 
attack from the hydroxy group.61 
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Scheme 2.3 Preparation of 1,3-Oxazine-4-Carboxylic Acid (4) 
The preparations of 1,3-thiazane-4-carboxylic acid and 2-methy1-1,3-thiazane-4­
carboxylic acid derivatives (5, 6, 7, 8 and 9) began with D,L-homocysteine thiolactone as 
starting material (Scheme 2.4). The lactone ring was opened under strongly alkaline 
condition (4 N NaOH) and the free homocysteine was reacted with formaldehyde to form 
the racemic 1,3-thiazane-4-carboxylic acid (15). An asymmetric transformation was 
achieved via salt formation with optically active tartaric acid in the presence of 
salicylaldehyde in acetic acid.62 Salicylaldehyde, as the catalyst in the asymmetric 
transformation, accelerates the racemization of the more soluble diastereomeric complex in 
solution. The optical active tartaric acids only complex with one of enantiomers and the 22 
less soluble diastereomeric salts precipitate from acetic acid. After collecting the salt, 
excess lead acetate was added to remove the tartate and then hydrogen sulfide was bubbled 
through the solution to precipitate excess lead acetate. Using D-tartaric acid leads to the 
conversion of the racemic 15 to (S)-1,3-thiazane-4-carboxylic acid (5), whereas L-tartaric 
acid gives rise to (R)-1,3-thiazane-4-carboxylic acid (6). 
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Scheme 2.4 Preparation of 5-Thia-L-Pipecolate Analogs 5 and 7 
By treating with hydroxylamine hydrochloride, optically active homocysteine was 
prepared from either the (R) or (S)-1,3-thiazane-4-carboxylic acid, which were obtained 
by the above asymmetric transformation. The (R) or (5) homocysteine was then 
condensed with acetaldehyde and the (2R, 4S) and (2S, 4R)-2-methy1-1,3-thiazane-4­
carboxylic acids (7 and 9) were obtained. When the (2R, 4S) and (2S, 4R)-2-methy1-1,3­
thiazane-4-carboxylic acids (7 and 9) were prepared, respectively, it appeared from the 23 
NMR spectra that the cyclization reaction was stereoselective with the carboxyl group 
oriented syn to the methyl group. This stereoselectivity can be explained by the fact that it 
is energetically most favorable for both groups to be located at the equatorial position of 
the six member ring. The configuration at C-2 was assigned from the 2D-NOESY data and 
the known absolute configuration of the carboxylic group at position 4. In the (2R, 4S) 
and (2S, 4R) enantomers, 7 and 9 respectively, a nOe interaction was observed between 
the protons at position 2 and 4 (Figure 2.3). 
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Figure 2.3 Observed nOe Interaction Between H-2 & H-4 in 7 and 9 
Compound 8, (2S, 4S)-2-methyl -1,3-thiazane-4-carboxylic acid, was prepared 
from the (2S, 4R) diastereomer (9) by reaction with D-amino acid oxidase at room 
temperature followed by reduction with sodium borohydride (Scheme 2.5).63 Although 
both (2S, 4S) and (2S, 4R) isomers are obtained after the reduction step, only the (2S, 
4R) diastereomer can be reoxidized by D-amino oxidase. After three oxidation-reduction 
cycles, the transformation from the (2S, 4R) isomer to the (2S, 4S) counterpart was 
complete as determined by NMR spectroscopy. In the spectra for the (2S, 4S) 
diastereoisomer (8), no nOe was observed between the protons at positions 2 and 4. 24 
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Scheme 2.5 Preparation of 5-Thia-L-Pipecolate Analogs 6, 8 and 9 
Preparation Of Pipecolate Analogs With Heteroatoms At Position 4 
To prepare (S)-1,4-thiazane-3-carboxylic acid (10), bromoethanol was condensed 
with L-cysteine under basic conditions to give (S)-2-hydroxyethyl-L-cysteine (17) 
(Scheme 2.6). This compound, upon heating in hydrochloric acid (38%), gave (S)-2­
chloroethyl-L-cysteine hydrochloride  (18).  Finally,  the chloride was cyclized  in 
dimethylformamide-triethylamine to yield 10.64 
To oxidize (S)-1,4-thiazane-3-carboxylic acid (10) to the sulfoxide 11, acid 
catalysis with hydrogen peroxide was chosen (Scheme 2.6).64 Sulfur, with its lone pair of 
electrons, needs an electrophilic oxidizing agent. It is known that hydrogen peroxide is in 
equilibrium with the protonated peroxide in an acidic medium, which is a stronger 
electrophile than the conjugate base.65  However, a nucleophilic attack to the sulfoxide 
group is necessary to further oxidize the sulfoxide to the sulfone analog 12. To do this, 
m-chloroperoxybenzoic acid (m-CPBA) in a basic medium was chosen (Scheme 2.6). 25 
Under basic conditions, m-CPBA is almost completely in the anion form, which is a 
stronger oxidizing form than the neutral molecule.66 
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Preparation of (R, S)-1,4-Piperazine-2-Carboxylic Acid (13) 
Catalytic hydrogenation of commercially available 2-pyrazinecarboxylic  acid 
yielded 1,4-piperazine-2-carboxylic acid (13) (Scheme 2.7). The reaction proceeds rapidly 
and cleanly with a palladium catalyst adsorbed on the inert carbon support. 26 
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Scheme 2.7 Preparation of (R, S)-1,4-Piperazine-2-Carboxylic Acid (13) 
MATERIALS AND METHODS 
All starting materials and reagents were purchased from commercial sources and 
were reagent grade or better. All organic solvents were distilled before use and air-
sensitive reagents were handled under an atmosphere of dry argon. Anhydrous reactions 
were done in oven-dried glassware and solvents for reactions were dried and freshly 
distilled according to Perrin et al.67 Water was double deionized and filtered (0.45 pm) 
prior to being used. Buffers were prepared with doubly deionized water and the pH was 
adjusted to the desired value at room temperature with a 4 N NaOH or 4 N HC1 solution. 
All melting points were uncorrected and determined with a Unimelt oil immersion 
apparatus using open capillary tubes. Optical rotations were measured on a Perkin-Elmer 
141 polarimeter with a 10.00 cm (5 mL) cell at ambient temperature. All specific rotations 
reported were measured at the sodium D line. Infrared spectra (IR) were recorded on a 
Nicolet 510P-LHS by the potassium bromide plate method. Nuclear magnetic resonance 
(NMR) spectra were measured on Bruker AC-300 instrument in the specified deuterated 
solvent. Chemical shifts for 1H-NMR are quoted in ppm and referenced to residual 
undeuterated solvent. For 13C-NMR, spectra were referenced to internal residual solvent 
or, for aqueous samples, an external standard of dioxane in D20. Mass spectra were 
obtained in the chemical ionization (CI), electron impact (EI) or fast atom bombardment 27 
(FAB) mode, as specified. Whenever possible, reactions were monitored by thin layer 
chromatography (TLC). TLC was performed on 0.25 mm aluminum-backed silica gel 
plates with ultraviolet indicator. Compounds were visualized using ultraviolet light or 
developed with bromocresol green spray for carboxylic acids and ninhydrin spray for 
amines. Flash chromatography was performed using silica gel (Merck type 60, 230-400 
mesh). Cation-exchange resin was Bio-Rad AG50W-X8 (H+ form, 100-200 mesh). 
Anion-exchange resin was Bio-Rad AG1-X8 (acetate form, 100-200 mesh). All ion-
exchange resins were regenerated according to the manufacturer's instructions and fully 
equilibrated and washed before used. 
(S)-1,2-Diaminobutyric acid (14) 
The procedure found in the literature was modified.57 Sodium azide (5.5 g, 85 
mmol) was added in small portions to a mixture of L-(+)-glutamic acid (7.35 g, 50 mmol), 
25 mL of concentrated sulfuric acid and 25 mL of chloroform over a period of 6 hours at 
45 °C. After overnight stirring, the reaction mixture was poured onto 200 g of ice and the 
resulting aqueous solution was treated with hot saturated barium hydroxide solution until 
the pH was 3. Barium sulfate was removed by centrifugation and the aqueous solution 
was reduced in volume to 100 mL under reduced pressure and applied to a 100 mL Bio-
Rad AG50W-X8 (11+ form, 100-200 mesh) ion-exchange column. The column was 
washed with 500 mL of water and then eluted with 500 mL of 0.1 N HC1. The volume 
was reduced to 10 mL under reduced pressure and 100 mL 95% ethanol was added to 
crystallize the product. Yield: 6.19 g, white needles (65%): mp 198-210 °C dec.; [(x]]) 
+14.7° (c 2.15, H2O) [lit.:68 m.p. 204 °C; DAD +15.1° (c 3.82, H2O)]; IR (KBr) 3051, 
1986, 1740, 1616, 1475, 1194 cm-1; 11-1-NMR (300 MHz, D20) 8 3.80 (1H, t, J=6.7 
Hz, CHCOOH), 2.98  (2H,  dd,  J=15.6,  7.1  Hz, NH2CH2),  2.26  (2H,  m, 
NH2CH2CH2); 13C-NMR (75 MHz, D20) 8 175.2 (CH3COOH), 54.5 (CHCOOH), 28 
38.9 (NH2CH2), 30.4 (NHCH2CH2); HREIMS: m/z 119.0821  (M+) [Calcd for 
Ci4HioN202: 119.0821]. 
(S)-1,4,5,6-Tetrahydropyrimidine-4-carboxylic acid (1) 
A 10 mL solution of (S)-1,4-diaminobutyric acid dihydrochloride (14) (250 mg, 
1.31 mmol) was applied to a 15 mL Bio-Rad AG50W-X8 (H+ form, 100-200 mesh) 
cation exchange column. After washing with 60 mL of deionized water, the column was 
eluted with 60 mL of 0.5 N ammonium hydroxide. The ninhydrin positive fractions was 
collected and dried down. Part of the residue (150 mg 1.25 mmol) was dissolved with 50 
mL water and placed in a 100 °C oil bath with formamidine hydrochloride (156 mg, 1.5 
mmol) for 3 hours. The mixture was cooled to room temperature and water was removed 
under reduced pressure. The residue was crystalized from water ethanol and 130 mg white 
needles was obtained (yield 81.3%): mp 252-253 °C dec.; NOD +187° (c 0.86, H2O); IR 
(KBr) 3389, 3154, 1680, 1616, 1496 cm-1; 1H-NMR (300 MHz, D20) 6 7.98 (1H,  s, 
CH=NH), 4.01 (1H, t, J=5.6 Hz, CHCOOH), 3.48 (1H, m, NHCH2CH2), 3.34 (1H, 
m, NHCH2CH2), 2.17 (2H, m, NHCH2CH2); 13C-NMR (75 MHz, D20) 8 178.4 
(POOH), 153.1 (CH=NH), 54.8 (CHCOOH), 39.2 (NHCH2CH2), 24.0 (NHCH2CH2); 
HRFABMS: m/z 129.0665 (MH+) [Calcd for CsH9N202: 129.0664] 
(S)-2-Amino-3,4,5,6-tetrahydropyrimidine-4-carboxy acid (2) 
A 50 mL aqueous solution of (S)-1,4-diaminobutyric acid (14) (0.525 g, 2.75 
mmol) was pH adjusted to 9.0 with 1 N sodium hydroxide solution and a 5 M cyanogen 
bromide acetonitrile solution (0.66 mL, 3.3 mmol) was added. After stirring at room 
temperature for 5 hours, the mixture was washed three times with ethyl acetate, then 
reduced to a volume of 10 mL and loaded onto a 100 mL Bio-Rad AG50W-X8 (H+ form, 
100-200 mesh) cation exchange column. The column was washed with 500 mL deionized 29 
water and eluted with 350 mL 0.1 N HC1. The solvent was removed under reduced 
pressure and the residue was crystallized from water and isopropanol at -20 °C. Yield: 130 
mg white needles (36% yield): mp 216 °C; NOD +120° (c 0.72, H2O) [lit:57 mp 211 °C; 
[a]r) +144° (c 1.08, H20)]; IR (KBr) 3431, 3325, 1662, 1604, 1562 cm-1; 1H-NMR 
(300 MHz, D20) 8 4.39 (1H, t, J=10.2 Hz, CHCOOH), 3.41 (2H, dt, J=2.4, 9.4 Hz, 
NHCH2CH2), 2.52 (1H, m, NHCH2CH2), 2.09 (1H, m, NHCH2CH2); 13C-NMR (75 
MHz, D20) 8 180.6 (COOH), 163.0 (NH2CH) 53.8 (CHCOOH), 41.4 (NHCH2CH2), 
25.9 (CH2CH2CH); HRFABMS m/z 144.0773 (MH+) [Calcd  for C5H10N302: 
144.0773] 
(S)-Hexahydropyrimidine-4-carboxy acid (3) 
To a 17 mL solution of (S)-1,4-diaminobutyric acid (14) (199.5 mg, 1.69 mmol) 
at 0 °C, 37 % aqueous formaldehyde (0.15 mL, 1.86 mmol) was added, dropwise, over 
half an hour and stirred at 0 °C for another half hour. After drying down the solution, the 
residual oil was crystallized from methanol and dichloromethane. Yield: 120 mg (55%): 
mp 191-192 °C; [a]r) +33.1° (c 0.21, H20); IR (KBr) 3271, 3127, 2955, 1635, 1585 
cm-1; 
1H-NMR (300 MHz, D20) 8 4.48 (1H, d, J=12.0 Hz, NHCH2NH), 4.05 (1H, d, 
J=12.0 Hz, NHCILI2NH), 3.62 (1H, dd, J=12.3 Hz, CHCOOH), 3.41 (1H, d, J=13.0 
Hz, NHCH2), 3.11 (1H, m, NHCH2), 2.15 (1H, d, J=14.6 Hz, CHCH2CH2), 1.76 
(1H, d, J=12.3 Hz, CHCH2CH2); 13C-NMR (75 MHz, D20) 8 178.9 (COOH), 60.8 
(NHCHNH), 59.1 CCHCOOH), 44.8 (CH2CH2NH), 28.9 (CH2CH2NH); HREIMS: 
m/z 129.0664 (Mt) [Calcd for C5H9N20: 129.0664] 
(R, S)-1,3-Thiazane-4-carboxylic acid (15) 
The procedure found in the literature was modified.62 A solution of D,L-1,3­
homocysteine thiolactone hydrochloride (1.0 g, 6.51 mmol) and sodium hydroxide (1.65 
g, 41.25 mmol) in 8 mL of deionized water was stirred at 0 °C for 30 minutes before the 30 
pH was adjusted to 6 with 6 N HC1. Formaldehyde (0.57 mL of 37% aqueous solution, 
7.81 mmol) was added and the reaction was stirred at room temperature for 5 hours. The 
solution was concentrated and 20 mL of acetic acid was added to extract the residue. The 
filtrate was collected and dried down. After acetic acid was used to extract the residue 
again, the crude product from the acetic acid filtrate was recrystallized from water and 
isopropyl alcohol. Yield: 670 mg (70%): mp 213-214 °C; [lit:62 mp 218-219 °C without 
crystallization from water and isopropyl alcohol]; IR (KBr) 3364, 2704, 1738, 1635, 
1564, 1431, 1377, 1290, 1250, 1205 cm-1; 11-I-NMR (300 MHz, CD3COOD) S 4.49 
(2H, dd, J=13.0 Hz, CH2NH), 4.05 (1H, d, J=10.4 Hz, CHCOOH), 3.04 (1H, t, 
J=13.7, 11.5 Hz, SCH2CH2), 2.88 (1H, d, J=13.7 Hz, SCH2CH2), 2.71 (1H, d, 
J=13.7 SCH2CH2), 2.27 (1H, dd, J=13.7, 11.5 Hz, SCH2CH2); 13C-NMR (75 MHz, 
CD3COOD) 8 177.9 (COOH), 63.0 (SCH2NH), 50.7 (COOHCH), 33.2 (SCH2CH2), 
31.0 (SCH2CH2); HRCIMS: ink 148.0432 (MH+) [Calcd for C5H10NO2S: 148.0432] 
(S)-1,3-Thiazane-4-carboxylic acid (5) 
The procedure found in the literature was modified.62 To a mixture of D,L-1,3­
thiazane-4-carboxylic acid (15) (1.44 g, 9.8 mmol) and D-tartaric acid (1.47 g, 9.8 mmol) 
in 8 mL of acetic acid at 80 °C was added salicylaldehyde (1.2 g, 9.8 mmol). After stirring 
the mixture for 6 hours and then one addition hour at room temperature, the resulting 
product was collected by filtration, washed first with 2 mL of acetic acid and then 
thoroughly with diethyl ether and dried. The residue was dissolved in 100 mL of water 
and 3 g of lead acetate were added within 10 minutes with stirring at room temperature. 
After the precipitate was filtered, the filtrate was saturated with hydrogen sulfide gas. The 
precipitate was removed and the filtrate was dried down in vacuo. The residue was 
crystallized from water and isopropyl alcohol. Yield: 278 mg (38.6%): mp 218-219 °C; 
NOD -12.2° (c 0.86, 1 N HC1) [lit:62 NOD -12.5° (c 1.00, 1 N HC1); mp 275-278 °C]; IR 
(KBr) 3437, 2919, 1736, 1631, 1431 cm-1; 111-NMR (300 MHz, D20) 8 4.34 (2H, q, 31 
J=13.2 Hz, SCI-J2NH2), 4.11 (1H, dd, J=11.8, 2.8 Hz, CHCOOH), 3.00 (1H, d, 
J=14.0 Hz, SCH2CH2), 2.84 (1H, d, J=14.0 Hz, SCH2CH2), 2.58 (1H, d, J=13.9 Hz, 
SCH2CH2), 2.10 (1H, m, SCH2CH2); 13C-NMR (75 MHz D20) 8 173.4 (COOH), 59.9 
(SCH2NH), 47.8 (CHCOOH), 29.8 (SCH2CH2), 28.0 (SCH2_CH2); HREIMS: m/z 
147.0354 (Mt) [ Calcd for C5H9NO2S: 147.0354]; Analysis: C, 40.65; H, 6.11; N, 9.28 
% [Calcd for C5H9NO2S: C, 40.81; H, 6.17; N, 9.52 %] 
(R ) -1 ,3 -T hi az an e - 4 - c ar b oxy c acid (6) 
The literature procedure was modified.62 To a mixture of D,L-1,3-thiazane-4­
carboxylic acid (15) (123 mg, 0.745 mmol) and L-tartaric acid (126 mg, 0.745 mmol) in 
2 mL of acetic acid at 80 °C was added salicyaldehyde (10.9 mg, 0.745 mmol). After 
stirring the mixture for 6 hours and then 1 hour at room temperature, the resulting product 
was collected by filtration and washed with 2 mL of acetic acid and a large amount of 
diethyl ether. The resulting product was crystallized from 1 N HC1 and isopropyl alcohol. 
Yield: 42 mg (38%): mp 223-224 °C dec.; [a]p +12.9° (c 0.856, 1 N HC1) [lit:62 [a]r) 
+12.5°(c 1.00, 1 N HC1), mp 275-277 °C]; IR (KBr) 3412, 1738, 1635, 1552 cm-1; 1H­
NMR (300 MHz, D20) 8 4.43 (2H, dd, J=13.2 Hz, SCH2NH), 3.75 (1H, d, J=10.3 Hz, 
CHCOOH), 3.03 (1H,  t,  J=11.6,  13.4 Hz, SCH2CH2), 2.86 (1H, J=14.6 Hz 
SCH2CH2), 2.61 (1H, d, J=14.6 Hz, SCH2CH2), 2.10 (1H, m, SCH2CH2); 13C-NMR 
(75 MHz, D20) 8 175.6 (COOH), 61.8 (SCH2NH), 47.6  ( CHCOOH), 30.5 
(SCH2CH2), 28.4 (SCHzCH2); HREIMS: m/z 147.0350 (Mt) [Calcd for C5H9NO2S: 
147.0354] 
(S)-Homocysteine (16) 
The literature procedure was modified.62 To 3 mL of freshly distilled ethanol 
solution of hydroxylamine hydrochloride (11.72 mg, 0.168 mmol), (S)-1,3-thiazane-4­
carboxylic acid (5) (124 mg, 0.84 mmol) in 5 mL of ethanol solution was added under 32 
reflux. Then, five portions of freshly distilled triethylamine (50 !IL, 0.168 mmol) and four 
portions of the ethanol solution of hydroxylamine hydrochloride (11.7 mg, 0.168 mmol) 
were alternately added to the reaction mixture at 10 minute intervals to keep the pH of the 
solution at 8. After refluxing the mixture for another hour, 0.1 mL of triethylamine was 
added and then the mixture was cooled to room temperature. The precipitate was collected 
by filtration, washed with a small amount of ethanol and dried. Yield: 60 mg (52.8%): mp 
242-244 °C dec.; [a]r, + 25.7° (c 0.752, 1 N HC1) [lit:62 mp 245-247 °C; [a]D, +26.8° (c 
1.00, 1 N HC1)]; IR (KBr) 2936, 2093, 1581, 1448, 1417, 1321 cm-1; 1H-NMR (300 
MHz, D20) 8 3.92 (1H, t, J=6.8 Hz, CHCOOH), 2.67 (2H, m, HSU-12), 2.17 (2H, dt, 
J=14.6, 6.4 Hz, HSCH2CH2); 13C-NMR (75 MHz, D20) 8 176.6 (COOH), 56.0 
(CHNH2), 37.0 (HSCH2), 22.2 (HSCH2_CH2); HRFABMS: m/z 136.0432 (MH+) 
[Calcd for C4H1oNO2S: 134.0432] 
(2R, 4S)- 2- Methyl -1,3- thiazane -4- carboxylic acid (7) 
To a stirred solution of (S)-homocysteine (16) (2.23 g, 16.5 mmol) in water (60 
mL), acetaldehyde (0.798 g, 18.14 mmol) was added, dropwise, over 1 hour and the 
mixture was stirred for 4 hours at room temperature. The precipitate was filtered and 20 
mL of acetic acid was used to extract the solid. The filtrate was collected and evaporated to 
dryness. The residue was crystallized from hot water and ethanol. Yield: 50 mg (19%): 
mp 198-199 °C; [a]r) -3.5° (c 0.43, 0.5 N HC1); IR (KBr) 2910, 2770, 1747, 1549  cm-1; 
1H-NMR (300 MHz, D20) 8 4.53 (1H, q, J=6.6 Hz, CH3CHS), 3.68 (1H, dd, J=13.8, 
2.8 Hz, CHCOOH), 3.15 (1H, dt, J=14.1, 2.6 Hz, CH2CH2S), 2.91  (1H, m, 
CH2CH2S), 2.63 (1H, qd, J=14.8, 2.8 Hz, CH2CH2S), 1.98 (1H, m, CH2CH2S), 1.65 
(3H, d, J=6.6 Hz, CI-J3CH); 13C-NMR (75 MHz, D20) 8 173.3 (COOH), 61.0 
(CH3CHS), 58.5 ( CHCOOH), 29.3 (CH2CH2S), 29.1 (CH2CH2S), 20.6 (CH3CHS); 
HREIMS: m/z 161.0511 (M+) [Calcd for C6H11NO2S: 161.0511] 33 
(2S, 4R)-2-Methyl -1,3-thiazane-4-carboxylic acid (8) 
To a 40 mL freshly distilled ethanol containing with (R)-1,3-thiazane-4-carboxylic 
acid (6) (6.53 g, 44.4 mmol) was added 70 mL of freshly distilled ethanol solution with 
hydroxylamine hydrochloride (0.57 g, 8.88 mmol). After refluxing the mixture in a 100 
°C oil bath, five portions of freshly distilled triethylamine (5.7 mL, 44.4 mmol) and four 
portions of the ethanol solution of hydroxylamine hydrochloride (2.3 g, 35.5 mmol) were 
added to the mixture at 10 minutes interval to keep the pH at 8. The reaction was refluxed 
for one addition hour before being cooled down to the room temperature. The precipitate 
was collected by filtration, washed with a small amount ethanol and dried. Then, it was 
redissolved with 100 mL of water and acetaldehyde (2.47 mL, 44.4 mmol) was added, 
dropwise, over a half hour period. The mixture was stirred for four hours at room 
temperature and concentrated to dryness under reduced pressure. The residue was 
crystallized from water and isopropanol at 4 °C. Yield: 80 mg white needles (11.7% ): mp 
197-198 °C; [a]D, +14.5° (c 0.77, 0.5 N HC1); IR (KBr) 2801, 1579, 1390, 1329, 1246, 
1199 cm-1; 1H-NMR (300 MHz, D20) S 4.61 (1H, m, CH3CHS), 4.08 (1H, d, J=12.8 
Hz, CHCOOH), 3.15 (1H, t, J=13.1, 12.0 Hz, CH2CH2S), 2.88 (1H, m, CH2CH2S), 
2.65 (1H, d, J=13.6 Hz, CH2CH2S), 2.01 (1H, m, CH2CH2S), 1.59 (3H, dd, J=6.2 
Hz, CH3CH); 13C-NMR (75 MHz, D20) 8 173.0 (COOH), 60.8 (CH3CHS), 58.5 
(CHCOOH), 29.2 (CH2CH2S), 29.0 (CH2CH2S), 20.6 (CH3CH); HRC1MS: mtz 
161.05111 (M+) [Calcd for C1211111102S: 161.0511] 
(2S, 4S )-2-Methy1-1,3-thiazane-4-carboxylic acid (9) 
To a solution of (2S, 4R)- 2- methyl -1,3- thiazane -4- carboxylic acid (8) (160 mg, 
0.93 mmol) in 4 mL of 0.5 M pH 8.0 potassium phosphate buffer, there was added 5 
units of porcine kidney D-amino acid oxidase suspension. After 45 minutes, sodium 
borohydride (9.6 mg, 2.38 mmol) was added followed by catalase (150 unit) 15 minutes 34 
later. The same cycle was repeated two more times after the catalase addition. The mixture 
was adjusted to pH 3.4 and centrifuged at 10,000 x g for 15 minutes to remove the 
precipitated protein. The filtrate was applied to a 30 mL Bio-Rad AG50W-X8 (H+ form, 
100-200 mesh) ion exchange column. After thoroughly washing with water, the column 
was eluted with 1 N NH4OH. The ninhydrin positive fractions were collected, pooled and 
concentrated. The residue was crystallized from water and isopropanol  at room 
temperature. Yield: 80 mg (53.3%): mp 194-195 °C; [43 +6.5° (c 0.74, 0.5 N HC1); IR 
(KBr) 2772, 2467, 1747, 1547, 1404, 1298, 1278, 1257 cm-1; 11-1-NMR (300 MHz, 
D20) 8 4.65 (1H, q, J=5.9 Hz CH3CHS), 4.14 (1H, d, J=12.8 Hz, CHCOOH), 3.25 
(1H, t, J=13.3 Hz CH2CH2S), 2.99 (1H, dd, J=13.8, 2.5 Hz, CH2CH2S), 2.76 (1H, d, 
J=14.8 Hz, CH2CH2S), 2.14 (1H, m, CH2CH2S), 1.70 (3H, d, J=5.5 Hz, CH3CH); 
13 C-NMR (75 MHz, D20) 8 173.2 (COOH), 60.8 (CH3CHS), 58.5 (CHCOOH), 29.2 
(CH2CH2S), 29.0 (CH2CH2S), 20.6 (CH3CH); HREIMS: m/z 161.0511 (M+) [Calcd 
for C6H1INO2S: 161.0511] 
1,3-Oxazane-4-carboxylic acid (4) 
To a stirred solution of D,L-homoserine (222.5 mg, 1.868 mmol) in 5 mL of 
water at room temperature, 37% aqueous formaldehyde solution (0.15 mL, 1.868 mmol) 
was added, dropwise, over a half hour period. The solution continued to stir for one hour 
at room temperature before being concentrated to dryness. The residue was crystallized 
from water and isopropyl alcohol. Yield: 268 mg (92%): mp 204 °C; IR (KBr) 3391, 
3289, 2991, 2845, 1593 cm-1; 1H-NMR (300 MHz, D20) 8 4.71 (1H, d, J=10.5 Hz, 
HNCI-J20), 4.33 (1H, d, J=10.5 Hz HNCH2O), 4.20 (1H, d, J=8.6 Hz, CHCOOH), 
3.86 (1H, t, J=10.3 Hz, OCH2CH2), 3.50 (1H, dd, J=11.4, 3.0 Hz, OCH2CH2), 1.94 
(1H, d, J=12.6 Hz, OCH2CH2), 1.79 (1H, m, OCH2CH2); 13C-NMR (75 MHz, D20) 
182.3  (COOH), 79.7  (NHC,H20),  69.3  (CHCOOH), 59.9  (CH2CH20),  32.9 
(CH2CH20); HREIMS: miz 130.0504 (M+) [Calcd for C5H8NO3: 130.0504] 35 
(S)-2-Hydroxyethyl-L-cysteine (17) 
The literature procedure was modified.64 To a solution of sodium hydroxide (254 
mg, 6.35 mmol) in 2.5 mL of water, L-cysteine (769 mg, 6.35 mmol) was added. 
Bromoethanol (952.5 mg. 7.62 mmol) was then added cautiously in small portions over a 
period of one hour after which 3 mL of 95% ethanol was added to the solution. The 
mixture was stirred at room temperature overnight before being dried down. The residue 
was redissolved with 10 mL of water and washed with 10 mL ethyl acetate three times. 
The aqueous layer was dried in vacuo and the crude product was crystalliwd from water 
and ethanol. Yield: 842 mg (80%): mp 187-188 °C; [a]D -52.5° (c 1.38, H2O) [lit.:64 mp 
189-190 °C; [a]D -53.3° (c 2.00, H2O)]; 1H-NMR (300 MHz, D20) 8 3.95 (1H, t, J=5.4 
Hz, CHCOOH), 3.78 (2H, t, J=5.9 Hz, HOCH2CH2), 3.18 (2H, m, HOCH2CH2), 2.79 
(2H, t, J=5.7 Hz, CH2CHCOOH); 13C-NMR (75 MHz, D20) 8 175.2 (COOH), 62.5 
(CHCOOH), 56.1 (HOCH2CH2), 36.1 (HOCH2CH2), 34.6 (CH2CHCOOH); LREIMS: 
m/z 165 (M+) [Calcd for C5H11NO3S: 165.0460] 
(S)-2-Chloroethyl-L-cysteine hydrochloride (18) 
The literature procedure was modified.64 A solution of 842 mg (5.1 mmol) of (5)­
2-hydroxyethyl-L-cysteine (17) in 20 mL of 38% hydrochloric acid was heated for 7 
hours at 95 °C and then concentrated to a white solid in vacuo. The crude product was 
crystallized from isopropyl alcohol. Yield: 700 mg white needles (75%): mp 183-184 C 
[lit:64 181.5-182°C]; [a]D -6.6° (c 0.65, H2O); IR (KBr) 2901, 1736, 1593, 1437, 1406, 
1352, 1300, 1228 cm-1; 1H-NMR (300 MHz, D20) 8 4.36 (1H,  t,  J=6.3 Hz, 
CHCOOH), 3.80 (2H, t, J=6.8 Hz, C1CH2CH2), 3.33 (2H, m, C1CH2CH2), 3.03 (2H, 
t, J=6.3 Hz, CH2CHCOOH); 13C-NMR (75 MHz, D20) 5 172.7 (CHCOOH), 54.8 
(CHCOOH), 45.9 (C1CH2CH2), 36.4 (CH2SCH2), 33.8 (CH2SCH2); LRFABMS: m/z 
183 (M+H)+ [Calcd for C5H10NO2SC1: 183.0121] 36 
(S)-1,4-Thiazane-3-carboxylic acid (10) 
The literature procedure was modified.64 To a solution of 660 mg (3.0 mmol) of 
(S)-2-chloroethyl-L-cysteine  hydrochloride  (18)  in  15 mL of  freshly  distilled 
dimethylformamide, there was added 5.4 mL (39 mmol) of freshly distilled triethylamine. 
A white solid precipitated. The mixture continued to stir in a 95 °C oil bath for 2.5 hours. 
The precipitate was collected and redissolved in 20 mL of water before being applied to a 
20 mL column of Bio-Rad AG50W-X8 (H+ form, 100-200 mesh) cation exchange resin, 
which was then washed with 200 mL of water and finally eluted with 75 mL of 1 N 
ammonium hydroxide. The nihydrin positive fractions were concentrated and crystallized 
from isopropyl alcohol and ethyl acetate. Yield: 270 mg white needles (61%): mp 261-262 
°C; [a]p -53.0° (c 0.1, H2O) [lit:64 mp 262-263 °C, [a]p -54° (c 1.6, H2O)]; IR (KBr) 
3072, 2885, 2278, 1606, 1469 cm-1; 1H-NMR (300 MHz, D20) 8 3.90 (1H, dd, J=10.1, 
3.3 Hz, CHCOOH), 3.77 (1H, td, J=13.2 3.2 Hz, CH2CH2NH), 3.38 (1H, m, 
CH2CH2NH), 3.17 (1H, m, CHCH2S), 3.06-2.94 (2H, m, CH2CH2NH, CHCH2S), 
2.84 (1H, m, CH2CH2NH); 13C-NMR (75 MHz, D20) 8 174.3 (COOH), 61.3 
(CHCOOH), 47.3 (CH2CH2NH), 29.5 (CH2S), 25.8 LCH2CH2NH); HREIMS: m/z 
147.0353 (M+) [Calcd for C5H9NO2S: 147.0354] 
(S)-1,4-Thiazane-3-carboxylic acid 1-oxide (11) 
The literature procedure was modified.64 To a suspension of (S)-1,4-thiazane-3­
carboxylic acid (10) (143.2 mg, 0.873 mmol) in 10 mL of acetic acid, 30% hydrogen 
peroxide (0.11 mL, 0.96 mmol) was added in 0.04 mL portions over a period of two 
hours with continuous stirring at 25 °C. The solution was allowed to stand at room 
temperature for one half hour and was then concentrated to an oil. The residue was 
crystallized from water and acetone. Yield; 65 mg white needles (46%): mp 249 °C; [a]c, 
+18.1° (c 1.03, H2O) [lit:64 mp 252 °C from H2O and ethanol, [a]r) +19.0° (c 1.0, H2O)]; 37 
IR (KBr) 3451, 1641, 1392, 1292, 1086 cm-1; 1H-NMR (300 MHz, D20) S 4.35 (1H, d, 
J=12.9 Hz, CHCOOH), 3.81-3.61 (3H, m, CH2S(0)CI-12CH,), 3.34 (1H, d, J=15.3 
Hz, CH2S(0)CH2), 3.19 (2H, m, CH2NH); 13C-NMR (75 MHz, D20) 8 173.7 
(COOH), 50.6 (CHCOOH), 46.2 (SCH2), 42.4 ((H2S), 36.4 ((H2NH); HREIMS: m/z 
163.0304 (M+) [ Calcd for C5H9NO3S: 163.0304] 
(S)-1,4-Thiazane-3-carboxylic acid 1-dioxide (12) 
To a stirred solution of (S)-1,4-thiazane-3-carboxyliclic acid 1-oxide (11) (254 
mg, 1.56 mmol) in 15 mL of 1 N NaHCO3 at pH = 10, m-chloroperoxybenzoic acid (455 
mg of 60% reagent, 1.56 mmol) was added by small portions over a two-hour period. 
After stirring the solution half hour at room temperature, adjusting the pH of the solution 
to 4 and filtering the precipitate, the solution was applied to a 10 mL Bio-Rad AG50W-X8 
(H+ form, 200-400 mesh) cation exchange column, which was then washed thoroughly 
with water and fmally eluted with 0.5 N ammonium hydroxide. The ninhydrin positive 
fractions were collected, pooled, dried down and the product was crystallind from water 
and acetone. Yield: 75 mg (26.9%): mp 220-221 °C; [a]p -2.6° (c 0.192, 1 N HCl); IR 
(KBr) 3364, 2995, 1716, 1398 cm-1; 1H-NMR (300 MHz, D20) 8 3.67 (1H, dd, J=9.1, 
2.5 Hz, CHCOOH), 3.51 (2H, m, CH2NH), 3.23 (4H, m, CH2S(0)2CH2); 13C-NMR 
(75 MHz, 1320) 5 61.3 ((HCOOH), 56.6 ((H2S), 53.1 (CH2S), 44.5 ((H2NH); 
HRFABMS: m/z 178.0174 (M-H)+ [Calcd for C5H8NO4S: 178.0174] 
1,4-Piperazine-2-carboxylic acid (13) 
To a suspension of 2-pyrazinecarboxylic acid (1 g, 8.1 mmol) in 40 mL of acetic 
acid, 5% palladium on carbon (50 mg) was added and the solution was stirred under a 
hydrogen balloon atmosphere (balloon pressure) overnight at room temperature. After 
decolorizing with charcoal three times, the solution was applied to a 20 mL Bio-Rad 38 
AG50W-X8 (H+ form, 100-200 mesh) cation exchange column, which was washed with 
80 mL water and then eluted with 1 N ammonium hydroxide. The ninhydrin positive 
fractions were collected, pooled, dried down and the product was crystallized with 1 N 
HC1 and isopropyl alcohol at room temperature. Yield: 10 mg (10 %): mp 249-250 °C; IR 
(KBr) 3026, 2812, 1757, 1633, 1533, 1435, 1388, 1319 cm-1; 1H-NMR (300 MHz, 
D20) 8 4.41 (1H, dd, J=11.1, 4.0 Hz, CHCOOH), 4.00 (1H,  d, J=14.0 Hz, 
CH2CHCOOH), 3.81-3.69 (2H, m, CH2CHCOOH, CH2NH), 3.57-3.40 (3H, m, 
NHCH2CH2NH); 13C-NMR (75 MHz, D20) 8 169.8 (COOH), 55.6 (CHCOOH), 44.3 
(CH2NH), 42.2 (CH2NH), 41.9 (CH2NH); HREIMS: m/z 130.0742 (14+) [Calcd for 
C5H10N202: 130.0742] 39 
CHAPTER 3 
KINETIC AND MECHANISTIC STUDIES OF ALTERNATE
 
SUBSTRATES AND INHIBITORS OF L-PIPECOLATE OXIDASE
 
One of the goals of this project was to gain insight into the chemical mechanism of 
L-pipecolate oxidase. Towards this goal, we have synthesized a variety of substrate 
analogs and studied the effect of each compound on the reaction catalyzed by L-PO. This 
chapter is largely concerned with the kinetic analysis of the reaction of L-PO with L­
pipecolate analogs because kinetic measurements of enzymatically catalyzed reactions are 
among the most powerful techniques for elucidating the catalytic mechanism of an 
enzyme. It is widely accepted that the rate of the enzymatic reaction and how this rate 
changes in response to different conditions is intimately related to the path followed by the 
reaction and is therefore indicative of its reaction mechanism. Through kinetic data, we can 
better understand the details of the various steps in the reaction process and the sequence 
in which they occur. To conduct such studies, the enzyme must first be isolated and 
purified. 
ENZYME ISOLATION AND ASSAY 
L-PO was isolated from Rhesus monkey liver following the method of Mihalik et 
al.18 The isolation is quite straightforward and makes use of some unique properties of L­
PO. First, the monkey liver was finely minced and homogenized. Through centrifugation, 
the membrane bound L-PO can be separated from soluble proteins. Because the protein is 
associated with the membrane rather than the soluble fraction, centrifugation results in a 
2.5-fold purification. After using detergent to disrupt the membrane and release L -PO into 
the solution, a heat treatment step was next employed to take advantage of the enzyme's 40 
heat-stability and another 2.5-fold purification was obtained. L-PO is more basic than most 
proteins with a pI of 8.9. The basic nature of the protein enabled a 13-fold purification by 
anion exchange chromatography on CM-cellulose resin in a single batch step. The high 
affinity of L-pipecolic oxidase for phenyl-sepharose, a hydrophobic resin, makes possible 
another 11-fold purification in a single step. This tight binding to phenyl-sepharose is due 
to the highly hydrophobic nature of this enzyme. The protein was judged to be about 90% 
pure as determined by SDS-polyacrylamide gel electrophoresis after this step. 
Two enzyme assay methods were used in this study and were described earlier in 
Chapter 1. The first is a spectrophotometric assay which couples hydrogen peroxide 
production from the oxidase reaction to the oxidation of o-dianisidine catalyzed by 
horseradish peroxidase.18 The second assay is more sensitive through the measurement of 
the radiolabeled reaction product, L-a-aminoadipate-8-semialdehyde.2° In this assay, 
sodium bisulfite is used to trap the semialdehyde. The bisulfite adduct has a net negative 
charge and is unretained on an AG50W-X8 cation exchange column, whereas the 
positively charged L-PA is bound. The detailed isolation and assay procedures can be 
found in the experimental section at the end of this chapter. 
KINETIC STUDIES OF SUBSTRATE ANALOGS 
Each of the thirteen compounds discussed in Chapter 2 was evaluated as an 
inhibitor or alternate substrate of L-pipecolate oxidase. These compounds were usually 
tested as an inhibitor first and then as a substrate. In the inhibition studies, 1 to 5 mM of 
the L-PA analog was incubated in the enzyme solution along with 3.5 mM L-PA (KM of 
the natural substrate). The activity of L-PO was monitored by spectrophotometric or radio-
assay. At the same time, a sample without analog was manipulated as a control. The 
degree of inhibition was determined by comparing the enzyme activity in the test and 
control samples. If a compound was found to decrease the enzyme activity in the inhibition 41 
experiment, a thorough analysis was carried out to determine the type of inhibition 
mechanism. 
To test compounds as alternate substrates, 1 to 5 mM of the L-PA analog was 
incubated with L-PO and  the  generation  of H202 was  monitored  using  the 
spectrophotometric assay. If a compound was found to serve as a substrate for the 
enzyme, the Michaelis constant (KM) and maximum velocity of the reaction (Vmax) were 
determined. In the simplest cases, KM can better be thought as an apparent dissociation 
constant for all enzyme bound species. KM is numerically equal to the substrate 
concentration at which the reaction velocity has attained half of its maximum value. 
Therefore, an enzyme with a high KM requires a higher substrate concentration to achieve 
a given reaction velocity than an enzyme with a low KM. The maximum velocity, Vmax, is 
the velocity when each enzyme active site is occupied by the substrate. The ratio Vmax /KM 
is an apparent second-order rate constant that relates reaction rate to the concentration of 
free enzyme. The higher this ratio, the more specific an enzyme is for a particular 
substrate.69 Several types of plots have been formulated for the determination of KM and 
Vmax from kinetic data. Among them, the Lineweaver-Burk plot (double-reciprocal plot), 
plotting 1/V vs KS], is the most commonly used and will be used here.  All 
spectrophotometric assays for the kinetic studies were run in duplicate and at the same time 
whenever possible. 
Characterization  of  (S)-1,3-Thiazane-4-Carboxylic  Acid  (5)  as  a 
Mechanism-Based Inhibitor 
When first tested as inhibitor and substrate of L-PO, (5)-1,3-thiazane-4-carboxylic 
acid (5) was thought to be only a substrate. However, during extended assays, non-linear 
progress curves were observed in the spectrophotometric assays which indicated time-
dependent inhibition. Therefore, the criteria for mechanism-based inhibitors were used to 
evaluate this compound.41 42 
Time- and concentration-dependent inhibition 
L-PO was preincubated with various concentrations of compound 5 and the 
enzyme activity was measured by spectrophotometery or radioactivity assays to determine 
the remaining activity and the level of inhibition. A time- and concentration-dependent 
inhibition of L-PO was observed (Figure 3.1). This means that at longer preincubation 
time or at higher inhibitor concentration, the lower will be the remaining activity of the 
enzyme. This suggests that after a rapid equilibrium between L-PO and 5, forming a 
simple complex, there is a slow reaction that converts the compound to the form that 
actually inactivates the enzyme. This results in a time-dependent loss of L-PO activity. 
Moreover, the rate of inactivation is proportional to the amount of (5)-1,3-thiazane-4­
carboxylic acid (5) until all L-PO molecules are saturated. The ICI and kinact were 
determined to be 43 mM and 0.06 midi respectively by the Kitz and Wilson method 
(Figure 3.2) using the spectrophotometric assay data.7° These results were confirmed by 
those from the radioassay. Using the radioassay, the same pattern of time- and 
concentration-dependent loss of activity was found and the K1 and kinact were determined 
to be 36 mM and 0.03 midi respectively. The intercept point of the y-axis in the Kitz and 
Wilson plot (Figure 3.2) is greater than zero, which indicates that saturation kinetics are 
followed and that specific binding occurs prior to inactivation.41 43 
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Figure 3.1 Time- and Concentration-Dependent Inhibition of L-PO by (S)-1,3-Thiazane-4­
Carboxylic Acid (5). 
(A: Spectrophotometric Assay; B: Radioassay) 
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Figure 3.2 Kitz and Wilson Plot of (S)-1,3-Thiazane-4-Carboxylic Acid. 
(A: Spectrophotometric Assay; B: Radioassay) 
Substrate protection 
Substrate protection can be used to demonstrate that an inactivator and L-PA bind 
to the same site on the enzyme. If (S)-1,3-thiazane-4-carboxylic acid (5) is a mechanism-
based inactivator, it will act as a modified substrate for L-PO and bind to the active site. 
Therefore, addition of substrate or a competitive inhibitor will slow down the inactivation 
400 44 
of enzyme in proportion to its concentration. The 1.5 and 3 hour preincubation studies at 
varied concentration of L-PA shows that the natural substrate can protect the inhibition of 
L-PO by compound 5 (Figure 3.3). These data prove that both (S)-1,3-thiazane-4­
carboxylic acid and L-pipecolate have the same binding site on the enzyme. 
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Figure 3.3 Substrate Protection of (S)-1,3-Thiazane-4-Carboxylic Acid (5) Inhibition by 
various concentrations of L-PA. 
Irreversibility of L-PO inhibition 
In most cases, mechanism-based inactivation results in the formation of covalent 
adducts with the enzyme. Consequently, dialysis does not restore enzyme activity. In this 
study,  following inactivation of L-PO,  the  preincubation  mixture was dialyzed 
exhaustively in order to remove excess and reversibly bound compound 5. A non-
inhibited control was carried through the same operation for comparison of L-PO activity. 
The results (Table 3.1) show there is only 12% recovery after seven hours dialysis and no 
increase after 18 and 27 hours dialysis. Therefore, the inactivation of L-PO by compound 
5 is irreversible. 45 
Table 3.1 Irreversibility of L-PO Inhibition by 5.
 
Dialysis Time (Hours) Recover Activity (%)
 
7  12% 
18  14% 
27  13% 
Test for inactivation prior to the release of an activated species 
In this experiment, the inactivation of L-PO by 15 mM (S)-1,3-thiazane-4­
carboxylic acid (5) was continuously monitored for 30 minutes at which time no activity 
remained. A fresh aliquot of enzyme was added and the rate of inactivation was 
monitored. If the inhibition is the result of indiscriminant inactivation by a released 
species, this reactive species will increase in the solution and the inactivation rate of the 
second aliquot of enzyme will be greater than that of the first one. For the inactivation of 
L-PO by 5, kobs (inactivation rate constant) was 2.55 x 10-3 min-1 for the first aliquot and 
2.40 x 10 3 min-1 for the second aliquot. Thus, the results indicate that the inactivation 
occurs prior to release of an activated species. 
Substrate kinetic parameters (Km and Vmax) for (S)-1,3-thiazane-4-carboxylic acid (5) 
When 5 was assayed as a substrate using the horseradish peroxidase- coupled 
assay, hydrogen peroxide was produced, indicating that (S)-1,3-thiazane-4-carboxylic 
acid (5) was turned over by L-PO. Figure 3.4 shows that the turnover of 5 by L-PO 
follows Michaelis-Menten kinetics. From the Linewear-Burk plot (Figure 3.4, insert), the 
apparent KM was determined to be 0.93 ± 0.16 mM with a Vmax of 0.09 ± 0.01 pmol 
min-1  mg-1. 0.012 
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Figure 3.4 Activity of L-Pipecolate Oxidase with (S)-1,3-Thiazane-4-Carboxylic Acid (5) 
as Substrate. Insert: Linewear-Burk plot used to estimate KM and Vmax. 
Taken together, these results indicate that (S)-1,3-thiazane-4-carboxylic acid (5) is 
a mechanism-based inactivator of L-PO. 
When (R)-1,3-thiazane-4-carboxylic acid (6) was tested as inhibitor and substrate 
of L-PO, it was found that this compound was neither an inhibitor nor a substrate. 
Preincubation studies also failed to produce inactivation of L-PO. This indicates that the 
inactivation of L -PO by 1,3-thiazane-4-carboxylic acid is stereospecific. 
Kinetic Study of (S)-1,4-Thiazane-3-Carboxylic Acid (10) and the Sulfur 
Oxidized Analogs (11 and 12) 
When testing the (S)-1,4-thiazane-3-carboxylic acid (10) as an inhibitor of L­
pipecolate oxidase, a higher reaction rate was observed when 1 and 3 mM 10 were 
present in the assay. This indicated that the compound is not a inhibitor but possibly a very 
good substrate. It was later confirmed with the substrate test. From the plot of the 
dependency of reaction velocity on the concentration of 10 (Figure 3.5), it was found that 47 
the L -PO catalyzed oxidation of compound 10 followed the Michaelis-Menten model and 
has KM of 0.42 ± 0.08 mM and Vmax of 0.11 ± 0.01 ilmolmin-1mg-1. The Vmax/Km is 
0.2 mLmin-1 .mg-1 for this compound which is almost four times greater than that with L­
PA as substrate. The V maxl Km provides a measure of catalytic efficiency and specificity of 
an enzyme for a substrate. Thus, it seems that (S)-1,4-thiazane-3-carboxylic acid (10) is a 
more efficient substrate for L-PO than the natural substrate. 
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Figure 3.5 Activity of L-PO as a Function of (S)-1,4-Thiazane-3-Carboxylic Acid (10) 
Concentration. Insert: Lineweaver-Burk Plot of the Data Used to Determination KM & 
Vmax-
When testing (S)-1,4-thiazane-3-carboxylic acid 1-oxide (11) as an inhibitor, it 
was found that L -PO was inhibited by 3 and 5 mM 11. However, there was no indication 
of turnover in the substrate test. Further kinetic tests were done in order to determine the 
type of inhibition and the inhibition parameters. The Lineweaver-Burk plot (Figure 3.6) 
shows that the inhibition is competitive and the Ki was determined to be 1.9 ± 0.3 mM. 48 
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Figure 3.6 Inhibition Study of (S)-1,4-Thiazane-3-Carboxylic Acid 1-Oxide (11). 
The sulfone analog, (S)-1,4-thiazane-3-carboxylic acid 1-dioxide (12), was also 
tested as an inhibitor of L-PO at 1 and 5 mM. Only weak inhibition was observed at 5 mM 
and no turnover by the enzyme was detected. This indicated that the compound was a 
weak inhibitor and not a substrate at all. The IC50 of 12 was determined to be 8.1 ± 0.1 
mM (Figure 3.7). 
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Figure 3.7 Inhibition Study of (S)-1,4-Thiazane-3-Carboxylic Acid 1-Dioxide (12). 49 
The results of (S)-1,4-thiazane-3-carboxylic acid (10) and its sulfoxide (11) and 
sulfone analogs (12) reveal that 10 is an excellent substrate, its sulfoxide analog 11 is just 
a moderate competitive inhibitor, and the sulfone analog 12 is only a weak competitive 
inhibitor. Thus, a polar functionality at position 4 of the pipecolate ring or the change in 
ring conformation that may result from oxidation of sulfur has a great effect on binding to 
L-PO. 
Kinetic Studies of Tetrahydro and Hexahydro Ring Compounds 
One purpose of synthesizing the (S)-2-amino-3,4,5,6-tetrahydropyrimidine-4­
carboxylic acid (2) was to test the effect of the basic guanidine group on binding to the 
GABA receptor. However, these experiments have not yet been conducted. Inhibition and 
substrate tests with L-PO were carried out and demonstrated that this compound is neither 
an inhibitor nor a substrate of the enzyme. 
One of the tautomers of (S)-3,4,5,6-tetrahydropyrimidine-4-carboxylic acid (1) is 
a structural mimic of A1-piperideine-6-carboxylic acid, which is the turnover product of L­
PA. Therefore, this compound was hoped to be a potent competitive inhibitor of L-PO. 
When tested with L-PO, 1 proved to be a weak competitive inhibitor and, as expected, 
was not turned over by the enzyme. The Ki for 1, determined from the Lineweaver-Burk 
plot shown in Figure 3.8, is 6.5 ± 0.2 mM. 50 
[I]=1 mM 
[I]= 0.5 mM 0.5 
0.4 
0.3 
0.2 
0.1 
0.0 
0.0	  1 . 0  2.0
 
1/[S] (1/mM)
 
Figure 3.8 Ki Determination for (S)-3,4,5,6-Tetrahydropyrimidine-4-Carboxylic Acid (1) 
Initial evaluation of (S)-hexahydropyrimidine-4-carboxylic acid (3) as a substrate 
of L-PO showed that this compound was turned over at concentrations of 1 and 5 mM. 
Further characterization shows that the KM is 10.3 ± 2.1 mM and the Vmax is 0.10 ± 0.01 
g 1 (Figure 3.9). Because the KM for 3 is three times greater than the KM of 
L-PA, it is classified as a poor substrate. 51 
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Figure 3.9: Activity of L -PO as a Function of (S)-Hexahydropyrimidine-4-Carboxylic 
Acid (3) Concentration. Insert: Lineweaver-Burk Plot of the Data Used to Estimate KM & 
Vmax 
For the evaluation of (R, S)- 1,3- oxazane- 4- carboxylic acid (4), the inhibitor and 
substrate tests were done at 1 mM, 3 mM and 5 mM. All the results indicate that 4 is 
neither a substrate nor an inhibitor of L-PO. Because of this, no further attempt was made 
to synthesize the (S) enantiomer from optically active homoserine. 
The inhibition test of (R, S)-1,4-piperazine-2-carboxylic acid (13) revealed weak 
inhibition at high concentrations (over 5 mM). The substrate analysis showed that 13 is 
not turned over by L-PO. As a result, no attempt was made to separate the (R) and (S) 
enantiomers. 
Table 3.1 provide a summary of the evaluation of the natural substrate, L-PA and 
the substrate analogs discussed in this thesis as inhibitors and substrates of L-pipecolate 
oxidase. Table 3.2 Summary of the Kinetic Data of Substrate Analogs 
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Compounds 
Vmax 
Km (mM) (prnolmin-1mg-1)  Ki (mM)  Comment 
(S)-3,4,5,6-Tetrahydropyrimidine-4-Carboxylic Acid (1)  6.5 ± 0.2  Competitive Inhibitor 
(S)-2-Amino-4-carboxy-3,4,5,6-Tetrahydropyrimidine (2) 
(S)-Hexahydropyrimidine-4-Carboxylic Acid (3)  10.3 ± 2.1  0.10 ± 0.01  Substrate 
(3S)-1,3-Oxazane-4-Carboxylic Acid (4) 
(S)-1,3-Thiazane-4-Carboxylic Acid (5)  0.93 -± 0.16  0.09 ± 0.01 
Substrate/
Mech. Based Inhibitor 
(2R, 4S)-2-Methyl-1,3-Thiazane-4-Carboxylic Acid (7)  0.31  ± 0.02  Competitive Inhibitor 
(3S)-1,4-Thiazane-3-Carboxylic Acid (10)  0.42 ± 0.08  0.11  ±0.01  Substrate 
(3S)-1-0xo-1,4-Thiazane-3-Carboxylic Acid (11)  1.89 ± 0.27  Competitive Inhibitor 
(3S)-1,1-Dioxo-1,4-Thiazane-3-Carboxylic acid (12)  8.08 ± 0.13  IC50 
L-Pipecolic Acid (14)  3.5  0.17  Natural Substrate 
14 53 
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Characterization  of  the  Turnover  Product  of  (S)-1,3- Thiaz ane -4 ­
Carboxylic Acid (5) 
Because the kinetic studies showed that (S)-1,3-thiazane-4-carboxylic acid (5) is a 
mechanism-based inactivator of L-PO, further characterization of the turnover product is 
necessary in order to elucidate possible inactivation  mechanisms. Possible inhibition 
mechanisms for 5 are drawn in Scheme 3.1 according to the proposed mechanism of L-PO 
(Scheme 2.1). There are several possible pathways for inactivation and product formation. 
The first possibility is the oxidation of the 1,3-thiazane ring to the sulfoxide analog by the 
hydrogen peroxide generated by the reoxidation of reduced flavin (pathway a). The other 
possibility is that after electron and proton transfer, an enzyme-1,3-thiazane  adduct is 
formed. If elimination takes place between the carbon sulfur bond in the thiazane molecule 
(pathway b), the enzyme will be inactivated. If elimination takes place between the flavin 
moiety and the thiazane molecule  (pathway c), 2,3dehydro-1,3-thiazane-4-carboxylic 
acid will be released and hydrolyzed to the 2-hydroxy-1,3-thiazane which is unstable. 
Spontaneous ring-opening would give either N-formyl or S-formyl L-homocysteine. The 
S-formyl group should rapidly hydrolyze yielding L-homocysteine and formic acid. 54 
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Scheme 3.1 Proposed Mechanisms for the  Reaction of (S)-1,3-Thiazane-4-Carboxylic
Acid (5) with L-Pipecolate Oxidase. 
To examine the existence of pathway a, an excess amount of catalase, which 
catalyzes the reduction of hydrogen peroxide  to water, was added to the assay solution. 
There was no change in the  enzyme activity when compared to the control without 
catalase. This confirmed that pathway a is not a dominant pathway of inactivation. 
To  obtain  basic  information  about  the  turnover  product,  p­
dimethylaminobenzaldehyde was added to the assay solution after incubating the enzyme 
with (S)-1,3-thiazane-4-carboxylic acid (5)  at 37 ''C for one and a half hours. A new 
absorption maximum was seen at 480 nm in the UV spectrum, which indicated that there 55 
was a free amino group in at least one of the turnover products and this free amino group 
reacted with p-dimethylaminobenzaldehyde.71 When two control samples, containing only 
(S)-1,3-thiazane-4-carboxylic acid (5) and L-PA  respectively, were reacted with  p­
dimethylaminobenzaldedehyde under the same conditions, neither sample produced  a 
product absorbing at 480 nm. 
In order to further characterize the turnover product, phenylisothiocyanate (PITC) 
was chosen as a derivatizing reagent. After incubation of the (S)-1,3-thiazane-4-carboxylic 
acid (5) with enzyme and derivitization, the solution was analyzed by reverse-phase (C18) 
HPLC. A new peak was identified which  had the same retention time  as authentic 
homocysteine-phenylthiohydantoin which was synthesized as a standard (Figure 3.10). 
This proves that one of the  turnover products is homocysteine. This finding  was 
confirmed by mass spectrometry. The mass of the isolated turnover product was measured 
to be 252.0391 which is the same  as that of the homocysteine phenylthiohydantoin 
standard (252.0391). Moreover, both the  isolated turnover product and the  standard 
compound have very similar ion patterns in the mass spectrum. 0.010 
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Figure 3.10 HPLC analysis of turnover product of 5 57 
Characterization  of  the  Turnover  Product  of  (S)-1,4-Thi azane-3­
Carboxylic Acid (10) 
The possible turnover mechanism for the (S)-1,4-thiazane-3-carboxylic acid (10) 
is shown in Scheme 3.2. Obviously, it is less complicated than that of 1,3-thiazane. After 
derivatizing with phenylisothiocyanate, the solution was analyzed on a C18 reverse phase 
HPLC column. Two control samples, one without 10 and one without L-PO were 
manipulated in the same way and analyzed under the same conditions. A new peak was 
found when compared to the controls. The mass of this peak is 279, which is the same 
mass as L-a-amino-4-thioadipate-8-semialdehyde-phenylthiohydantoin. A standard was 
not prepared for this metabolite. 
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Scheme 3.2 Mechanism of Turnover and Product Characterization for (S)-1,4-Thiazane-3­
Carboxylic Acid (10) 
DISCUSSION 
Thirteen substrate analogs of L-pipecolic acid were synthesized and tested as 
inhibitors or substrates of L-PO. The results of kinetic analyses indicated quite different 
binding behavior of these analogs with different functional groups. Because one aspect of 
the ',PO mechanism is the probable formation of a radical intermediate in some stage of 
the reaction, the well-developed theories about organic radical species and the proposed 
enzyme mechanism can be used to interpret the above kinetic data. Forming a radical is a 
highly unfavorable thermodynamic process in solution; the oxidation potential for a typical 
amine is about +1.5 V and the reduction potential for free flavin is -0.25 V.45 As a result, 58 
any structural feature that can stabilize a radical intermediate should lower the required 
energy and favor the reaction. 
A set of stabilization energies for different substitute groups was reported by Ohno 
(Table 3.2).72 From Table 3.2, it is seen that the stabilization energies between -OCH3 
and -CH3 are small. As a result, the resonance participation from an oxygen atom is not 
great. However, sulfur shows a very large stabilization energy indicating lower activation 
energies and implying the prominent participation of the sulfur atom in the stabilization of 
the radical center at the a-position. A similar conclusion was reached when studying 
hydrogen atom abstraction to form a radical.73 This can be attributed to the electron 
sharing and the electron transfer resonance structure. 
Table 3.2: Stabilization Energies (SE) for Carbon-Centered Radicals with Different 
Functional Groups 
Function Group  Stabilization Energy 
(kcal/mol) 
-CH3  4.6 
-OCH3  6.4 
-SCH3  12.1 
The large degree of stabilization of a carbon-centered radical by sulfur but not by 
oxygen could be a reasonable explanation for the turnover of (S)-1,3-thiazane-4­
carboxylic acid (5) by the enzyme, whereas (R, S)-1,3-oxazine-4-carboxylic acid (4) is 
neither a substrate nor an inhibitor. 
E.S.R. spectroscopy has been employed to study carbon-centered radicals with 
sulfur, sulfinyl- and sulfonyl- at the 0-position by comparing the hyperfine splitting ratio 
of the ri proton and a proton.74 It was found that the thio group could delocalize 22% of 
the spin density from the f3- carbon radical while the sulfinyl- could only delocalize 6% of 59 
the unpaired spin, and the sulfonyl group was wholly ineffective at removing spin density. 
This may partially explain why (S)-1,4-thiazane-3-carboxylic acid (10) is an excellent 
substrate, the sulfoxide analog 11 is just a moderate competitive inhibitor, and the sulfone 
analog 12 is a weak competitive inhibitor. In the same study,74 it was also found that a 
thio group is a more effective acceptor of spin density than alkyl and alkoxy substitutes. 
This provides further evidence why (S)-1,4-thiazane-3-carboxylic acid (10) is more 
effectively turnover than the natural substrate, L-pipecolic acid. 
MATERIALS AND METHODS 
Materials: All reagents were purchased from Sigma or Fisher. Monkey liver was 
obtained from Oregon Regional Primate Research Center. Water was double-deionized 
(NANOpure, Barnstead) and filtered (0.45 mm). Buffers were prepared with double 
deionized water and the pH was adjusted to the desired value at room temperature with 4 
N NaOH or 4 N HC1 solutions. Spectrophotometric studies were performed using a 
Hitachi U2000 spectrophotometer. D,L42,3,4,5,6-311]-Pipecolic  acid was custom-
synthesized by Amersham. The resulting D,L42,3,4,5,6-311]-pipecolic acid (D,L- [3H] -PA) 
had a specific activity of 6200 mCi/mmol and was separated from its radiolytic degradation 
products and converted to the homochiral L-form by the method of Mihalik and Rhead.16 
L- [3H]- Pipecolic acid was stored at -86 °C at a concentration of 10 mM and a specific 
activity of 500 1.1Ci/gmol. Radioactivity was determined on a Beckman LS 6000SC or a 
Beckman LS 6800 liquid scintillation counter. HPLC analyses were carried out on a 
Beckman Gold System using a 4.6 x 100 mm (3 pm) reverse phase (C18) Microsorb-MV 
column from Rainin. Kinetic parameters were calculated using the Enzyme Kinetics 
software package from Trinity Software. Plots were constructed with either Enzyme 
Kinetics or Cricket Graph 1.3 software package from Cricket Software. 60 
L-Pipecolate Oxidase Purification 
Homogenization and Solubilization  Frozen Rhesus monkey liver (100 g) was 
finely minced and then homogenized in a Waring blender in 300 mL of 250 mM sucrose 
containing 1 mM MOPS, pH 7.4 and 0.1 mM EGTA with protease inhibitors (0.1 mM 
benzamidine, 0.4 mg/mL leupeptin and 0.7 mg/mL pepstatin). This homogenate was 
centrifuged at 24,000 x g for 10 minutes. The supernatant was discarded, and the pellet 
was re-suspended in another 250 mL of the same buffer, then homogenized and 
centrifuged as above. The residue pellet was re-suspended in 150 mL of 100 mM KC1, 50 
mM HEPES, pH 8.0, 1 mM EGTA and 0.1% CHAPS buffer. The pellet suspension was 
magnetically stirred for 30 minutes, followed by 30 minutes centrifugation at 27,000 x g. 
The supernatant was decanted. The residual pellet was then re-suspended in 100 mL of the 
same buffer and stirred again for 30 minutes. After a repeat centrifugation as above, both 
supernatants were combined. 
Heat Treatment: The combined supernatants were rapidly brought to 45 °C and 
held at this temperature for 10 minutes. Then, the solution was rapidly cooled to 4°C in ice 
and centrifuged at 27,000 x g for 30 minutes. The supernatant was retained. 
CM-Cellulose Batch Chromatography: Whatman CM-cellulose cation exchange 
resin (75 g) was equilibrated with 5 mM KC1, 5 mM HEPES, pH 7.8 and 0.1 mM EGTA 
after it was treated with 0.5 M KC1, 5 mM HEPES, pH 7.8. The supernatant from the 
previous step was adjusted to pH 7.65 with 1 M HEPES, pH 6.8 and then diluted ten-fold 
with deionized water at 4 °C. This solution was stirred for 30 minutes with 125 mL of 
CM-cellulose resin. The suspension was transferred to a Buchner funnel lined with 
Whatman #1 filter paper. The resin was separated from the supernant and then washed 
with about 600 mL equilibration buffer. An enzyme-enriched fraction was eluted with 150 
mM KC1, 5 mM HEPES, pH 7.8 and 0.1 mM EGTA. 
Phenyl-Sepharose Chromatography: The active fraction from the prior step was 
adjusted to 0.5 M (NH4)2SO4, 25 mM KC1, 12.5 mM HEPES, pH7.8 and 0.25 mM 61 
EGTA and applied to a 10 mL column of Toso-Haas TSK-GEL Phenyl Sepharose 5-PW 
resin at 4 °C. The column was washed with 30 mL of 0.5 M (NH4)2SO4, 25 mM KC1, 
12.5 mM HEPES, pH 7.8, 0.25 mM EGTA at a flow rate of 1.0 mL/min. A stepwise 
elution was carried out using consecutive 13 mL volumes of 0.25 (NH4)2SO4, 0.1 M 
(NH4)2SO4 and loading buffer (without ammonium sulfate) at a flow rate of 1.5 mL/min. 
The enzyme activity was located in the 0.1 M ammonium sulfate fractions. 
Enzyme Assay of L-Pipecolic Oxidase Activity 
Spectrophotometric Assay. In a 500 pL optical glass spectroscopy cuvette, 
containing 40 mM Tris, 80 mM KC1, 0.8 mM EGTA, pH 8.5 buffer with 0.32 mM o­
dianisidine (5 pi. of 10 mg/mL stock solution) and 1.8 unit of horseradish peroxidase (5 
LL of 3.6 unit/10 !IL stock solution), different amounts of the enzyme solution and/or L­
pipecolic acid (20 mg/mL stock solution) were mixed along with the test compound. The 
absorption change at 460 nm was monitored and the reaction was kept at 37 °C. In most 
assays, enough enzyme was added to provide at least 0.015 absorbance units change per 
second. 
Radioassay. An indicated amount of enzyme solution was added to 10 mM 
NaHSO3, 225 pM L42,3,4,5,6-3H]-pipecolic acid, 60 mM Tris buffer (pH 8.5) and 
adjusted to a final volume of 200 pL. The preparation was incubated in a 37 °C water bath 
for 1 hour. The reaction was stopped by adding 25 pl.. of 1 N HC1 and samples were 
immediately applied to a 2.5 mL Bio-Rad AG50W-X8 (H+, 100-200 mesh) cation 
exchange column, which was equilibrated with deionized distilled water. Then the column 
was eluted with deionized water at gravity flow rate. The elutant was mated with 
scintillation cocktail and counted on a liquid scintillation counter. Two parallel blanks 
omitting either enzyme or L- [2,3,4,5,6 -3H]- pipecolic acid were run for each sample. 62 
Testing  Compounds  as  Inhibitors  and/or  Substrates  of  L-Pipecolate 
Oxidase 
Testing Compounds as Inhibitors : Assays were conducted at 37 °C in 40 mM 
Tris, 80 mM KC1, 0.8 mM EGTA, pH 8.5 buffer containing 3.5 mM L-PA, 0.32 mM o­
dianisidine and 1.8 units of horseradish peroxidase and the indicated concentration of L­
PA analog. The reaction was initiated by the addition of L-PO. 
Testing Compounds as Alternate Substrates: Assays were conducted at 37 °C in 40 
mM Tris, 80 mM KC1, 0.8 mM EGTA, pH 8.5 buffer containing L-PO, 0.32 mM o­
dianisidine and 1.8 unit of horseradish peroxidase. Reactions were initiated by adding the 
test substrate. 
Evaluation of (S)-1,3-Thiazane-4-Carboxylic Acid (5) as a Mechanism-
Based Inactivator of L-Pipecolate Oxidase 
Time- and Concentration-Dependent Inhibition: Purified L -PO was incubated with 
the 1 to 10 mM of 5 in 40 mM Tris, 80 mM KC1 and 0.8 mM EGTA, pH 8.5 buffer in a 
total volume of 250 tiL at 25 °C in the dark. At the times indicated, 25 til aliquots were 
removed and diluted with 475 IlL 37 °C assay cocktail. In the radioassay, the total volume 
of incubation solution was 90 ii.L. Each time, 11 !IL of aliquot were removed and diluted 
with 389 !IL of radioassay cocktail with 1 hour incubation before assay. 
Substrate Protection from Inhibition: L-PO was incubated with 5 mM 5 in 80 mM 
Tris, 160 mM KC1, 1.6 mM EGTA, pH 8.5 buffer with the indicated concentration of L­
PA in a total volume of 100 ilL at 25 °C in the dark. After 1.5 hr and 3 hr, 25 !IL aliquot 
of solution were removed and the activity was assayed. 
Reversibility of Inhibition: After incubating L-PO in 250 tiL of 40 mM Tris, 80 
mM KC1, 0.8 mM EGTA pH 8.5 buffer with 20 mM 5 for 4 hours in a total volume of 
500A at 25 °C, the solution was dialyzed against 600 mL buffer at 4 °C. Several buffer 
changes were made during the 28 hour dialysis. 50 'IL of reaction solution were removed 63 
at 7 hours,  18 hours and 27 hours to assay for recovered enzyme activity. A 
noninactivated control was carried through the same procedure. 
Test for Release of Active Species: L-PO was incubated with 15 mM 5 in 250 ;.11, 
of 40 mM Tris, 80 mM KC1, 0.8 mM EGTA, pH 8.5 buffer containing 0.64 mM o­
dianisidine and 3.6 unit of horseradish peroxidase in a 0.5 mL optical glass spectroscopy 
cuvette at 37 °C. Enzyme activity was continuously monitored by following the increased 
absorption at 460 nm. After 30 minutes, a fresh aliquot of enzyme was added to the 
solution and enzyme activity was monitored for another 30 minutes. 
Characterization of the Enzyme Turnover Product of (S)-1,3- Thiazane-4­
Carboxylic Acid (5) 
After incubating L-PO in 40 mM Tris, 80 mM KC1, 0.8 mM EGTA pH 8.5 buffer 
containing 10 mM substrate in a volume of 50 'IL in the dark overnight, 50 !IL of pyridine 
was added to terminate the reaction. Then, 1 ill of phenylisothiocyanate was added and the 
mixture was incubated at 37 °C for 20 minutes. After adjusting the pH of the solution to 
1.5 with 1 N HC1, the solution was centrifuged at 9000 x g and the precipitate was 
collected. The precipitate was dissolved in a minimum amount of 1 N HC1 and underwent 
analysis using reverse phase HPLC in a solvent system of 0.1% trifluoroacetic acid and 
acetonitrile. A no-enzyme control sample and a no-substrate control sample were treated 
under the same conditions. 
Characterization of the Enzyme Turnover Product of (S)-1,4-Thiazane-3­
Carboxylic Acid (10) 
After incubating L -PO in 40 mM Tris, 80 mM KC1, 0.8 mM EGTA pH 8.5 buffer 
containing 10 mM 10 in a total volume of 25 !IL in the dark overnight at room 
temperature, 25 µL of pyridine was added to terminate the reaction.  Then, 2µL of 
phenylisothiocyanate was added and the reaction was incubated at 37 °C for 30 minutes. 
After adding 50 jiL of 1 N HC1, the solution was centrifugated at 9000 x g. The 64 
supernatant was subjected to reverse-phase HPLC analysis in a solvent system of 0.1% 
trifluroacetic acid and acetonitrile. A no-enzyme control sample and a no substrate control 
sample were treated under the same condition. 65 
CHAPTER 4 
CONCLUSIONS 
L-Pipecolic acid (L-PA) is an intermediate of lysine degradation in various 
organisms. There are two primary pathways for lysine degradation in mammalian 
systems. In the central nervous system (CNS), the major pathway is the pipecolate 
pathway in which the first step is oxidation of L-PA by a peroxisomal oxidase, L­
pipecolate oxidase (L-PO). In this pathway, the L-PA oxidation is the rate-limiting step. As 
a result, studying the inhibition of L-PO through the effects of various synthetic inhibitors, 
especially mechanism-based inactivators, is a good approach to studying the L-PO 
mechanism and lysine degradation in the CNS. In this thesis, thirteen substrate analogs 
have been synthesized and tested for their ability to affect L-PO which has been isolated 
from Rhesus monkey liver. 
The kinetic analyses of these substrates were done using spectrophotometric and 
radioassays. It was found that (S)-3,4,5,6-tetrahydropyrimidine-4-carboxylic acid (1) is a 
competitive inhibitor with apparent Ki of 7.3 mM. (S)-3,4,5,6-Hexahydropyrimidine-4­
carboxylic acid (3) proved to be a weak substrate with apparent KM of 10.2 mM. All 
testing data indicate that the (S)1,3-thiazane-4-carboxylic acid (5) is a mechanism-based 
inactivator, with apparent Ki and kinact of 36 mM and 0.06 mind respectively. As a 
substrate, apparent KM and Vmax for 5 were determined to be 0.93 mM and 0.1 
g. 1, respectively. It was found that the inhibition of L-PO by (S)-1,3­
thiazane-4-carboxylic acid (5) was time- and concentration-dependent. The inhibition is 
irreversible and the enzyme is protected by natural substrate. It was also shown that the 
inactivation by 5 occurs prior to release of a highly reactive species. It was shown that 
(R)-1,3-thiazane-4-carboxylic acid (6) is neither a substrate nor an inhibitor, which 
indicates that the inhibition is stereospecific. The testing shows that (S)-1,4-thiazane-3­66 
carboxylic acid (10) is an excellent substrate with apparent KM of 0.42 mM and Vmax of 
0.1 p.molmin-i.m --1. Its high Vmax/Km ratio (0.2 mLmin-i.mg -1 ) indicates that 10 is a  g 
better substrate than the natural substrate. The sulfoxide derivative of 10, (S)-1,4­
thiazane-3-carboxylic acid 1-oxide (11) is just a moderate competitive inhibitor with 
apparent Ki of 2.7 mM. The sulfone derivative, (S)-1,4-thiazane-3-carboxylic acid 1­
dioxide (12), is only a weak competitive inhibitor with an IC50 of 8.1 mM. The studies 
also indicated that  (S)-2-amino-3,4,5,6-tatrahydropyrimidine-4-carboxylic  acid  (2), 
(R,S)-1,3-oxazine-4-carboxylic acid (4) and (R, S)-1,4-piperazine-2-carboxylic acid (13) 
served as neither substrates nor inhibitors. 
Further characterization of the turnover products for (S)-1,3-thiazane-4-carboxylic 
acid (5) and (S)-1,4-thiazane-3-carboxylic acid (10) was performed. After reacting the 
substrate analogs with L-PO, the mixture was treated with phenylisothiocyanate and 
analyzed by reverse phase HPLC. It was found that homocysteine was one of the turnover 
products  of  (S)-1,3-thiazane-4-carboxylic  acid  (5).  L-a-Amino-4-thioadipate-8­
semialdehyde was shown to be the turnover product of (S)-1,4-thiazane-3-carboxylic acid 
(10). 67 
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